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1. INTRODUCTION 
1. Introduction 
Feline herpesvirus-1 (FHV-1)-infection, also known as feline viral rhinotracheitis 
(FVR) has a world wide distribution in the cat population, with a high incidence in 
colony cats (>70 %). FHV-1 typically infects and replicates in epithelial tissue of 
the upper respiratory tract and conjunctiva causing cytopathic lesions. The virus 
is recognized as one of the most important pathogens of feline upper respiratory 
tract infections, conjunctivitis and keratitis. Following primary infection, over 80% 
of cats are unable to eliminate the virus and develop a carrier state, with 
intermittent episodes of virus shedding. During latency, the virus persists most 
frequently in the trigeminal ganglion, and the disease can be reactivated following 
stress and corticosteroid therapy. Successful treatment, particularly of ocular 
manifestations associated with recrudescent infection such as dendritic ulcers, 
remains difficult in the cat. Although a number of antiviral drugs are licensed for 
the use in humans the application for cats is limited. Available antiviral drugs are 
virostatic, and particularly the systemic application is associated with severe toxic 
side effects. Lately, use of interferons has been reported for the treatment of viral 
infections in veterinary medicine.  
Interferons are members of the cytokine family that play an important role as 
mediators of the innate (nonspecific) immune system. Among their multifunctional 
properties, they have antiviral, antiproliferative and immune regulatory functions. 
Although there is only minimal data available to support treatment with human 
alpha interferon (rHuIFN-α) (FULTON AND BURGE, 1985; NASISSE ET AL., 1996A), it 
has been recommended for the treatment of feline herpesvirus infection     
(GOULD, 1998; STILES, 2000). A recombinant feline omega interferon (rFeIFN-ω) 
has become commercially available (SAKURAI ET AL., 1992) and initial studies 
have assessed the antiviral properties of rFeIFN-ω against canine and feline 
virus infections (MOCHIZUKI ET AL., 1994, TRUYEN ET AL., 2001). Both these 
studies reported promising in vitro effects of the recently available rFeIFN-ω 
against FHV-1 infection. MOCHIZUKI and co-investigators (1994) assessed its 
antiviral activity at 100 U/ml and 1,000 U/ml and TRUYEN and co-investigators 
(2001) evaluated the anti-FHV-1 effect at 50,000 U/ml.  
Objectives of this study were to evaluate and compare the antiviral efficacy 
across a wider range of concentrations (100 U/ml - 500,000 U/ml) of rFeIFN-ω 
(Virbagen®-ω) and rHuIFN-α2b, (Intron®-A) on the replication of feline 
herpesvirus-1 (FHV-1) in vitro. This range was chosen in order to repeat 
previously studied concentrations, to determine whether the drugs have a dose-
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dependant response of antiviral activity and which concentration would be the 
most effective treatment against FHV-1 in CRFK-cells. The species-specificity of 
type I interferons is well known and therefore, it was suggested that rFeIFN-ω 
would result in a more profound effect compared to the rHuIFN-α2b due to its 
homologous nature. In addition to cell and virus culture techniques, a 
methodology for the plaque reduction assay was established. Furthermore, for 
the first time antiviral efficacy for interferon was additionally measured by plaque 
size reductions and is reported in this study. An in vitro MTT-Assay was 
integrated in the experiment to exclude possible cytotoxic effects that could, in 
principle, contribute to the antiviral effect of both interferons. 
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2. Literature Review 
2.1. Feline Herpesvirus-1 
2.1.1. Classification 
The herpesvirus family is comprised of five subfamilies: Alpha-, Beta-, Gamma-
herpesvirinae and an unnamed subfamily. The subfamilies are divided into 
genera based on DNA sequence and protein homology, but the taxonomy has 
not yet been fully established (MURPHY ET AL., 1999, ROIZMAN AND PELLETT, 
2001).  
Feline herpesvirus-1 (FHV-1) has been classified as a member of the subfamily 
Alphaherpesvirinae based on structural, genomic, physiochemical and replicative 
properties by the International Committee on Taxonomy of Viruses (ICTV, 
available from: URL:http://www.ncbi.nlm.nih.gov/ICTV). Prototypical members of 
the alphaherpesvirus subfamily are human herpesvirus-1 (herpes simplex virus, 
HSV-1; genus Simplexvirus) and human varicella-zoster virus (VZV; genus 
Varicellovirus). Besides FHV-1 there are many alphaherpesviruses relevant to 
veterinary practice, such as the etiologic agents of Marek’s disease (GHV-2; 
unnamed genus) and Pseudorabies (Aujeszky’s disease, PHV-1) (ROLLE ET AL., 
1993; MURPHY ET AL., 1999).  
 
2.1.2. Characteristics 
As most alphaherpesviruses, FHV-1 is composed of the four major structural 
elements including (a) an electron-opaque core, (b) an icosahedral capsid, (c) a 
tegument, and (c) an envelope (NASISSE AND WEIGLER, 1997; MURPHY ET AL., 
1999). FHV-1’s single molecule of linear double stranded DNA (dsDNA) is 
wrapped around the fibrous spool-like core, which is anchored inside the capsid. 
The capsid, 1200 Å in diameter, consists of 150 hexameric and 12 pentameric 
capsomers, a structural characteristic of all herpesviruses. The capsomers are 
hollow with a channel running along their inner axis. The capsid is surrounded by 
an amorphous structure called the tegument (ROIZMAN AND FURLONG, 1974; 
ROIZMAN AND PELLETT, 2001). The outer layer of the virion is formed by a fragile 
lipoprotein envelope, which carries about 12 viral glycoprotein (gp) spikes 
(peplomeres) on its surface. These glycoproteins play an important role during 
the initiation of infection (described in detail 2.1.3.) (ROIZMAN AND KNIPE, 2001). 
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Within the alphaherpesvirus family, the length (125 – 229 kb), conformation, and 
base composition (Guanin + Cytosin ratio variation of 32 – 74 %) of the genome 
varies considerably. The DNA strand of alphaherpesviruses is divided into two 
singular sequences: (a) the singular large domain (UL) and (b) the singular small 
domain (US) (ROIZMAN AND KNIPE, 2001). Reiterated DNA sequences occur at 
both ends of the strand and play a role in producing different genome isomers 
during viral replication (MURPHY ET AL., 1999). The FHV-1 genome is 126 - 134 kb 
in length and is composed of a 99 – 104 kb UL domain and a 27 – 30 kb US 
domain (ROTA ET AL., 1986; GRAIL ET AL., 1991).  
The gene products accomplish multiple functions during the life cycle of the 
virion. Some of these viral proteins interact with host cellular proteins and have 
become crucial for virus attachment, entry, replication, packaging and budding 
while other viral proteins block physiological host cell processes and interactions 
(described in detail in 2.1.3) (ROIZMAN AND KNIPE, 2001). The gene for the FHV-1 
thymidine kinase (TK), one of the herpesvirus-encoded enzymes located on the 
UL domain, has been studied in detail and has been shown to play an important 
role during viral replication (NUNBERG ET AL., 1989).  
The host range within the alphaherpesvirinae family is highly variable, ranging 
from a single host species to a broad spectrum of hosts (MURPHY ET AL., 1999). 
Properties of alphaherpesvirus infection include a short period of replication, 
rapid spread in cell culture, and a cytopathic effect resulting in destruction of 
infected cells. All alphaherpesviruses are known to persist in infected host 
organisms, primarily in sensory ganglia (MURPHY ET AL., 1999). During latency, 
the alphaherpes genome may be present within the cytoplasm as an 
extrachromosomal DNA element and may encode a latency-associated gene 
(MURPHY ET AL., 1999; ROIZMAN AND PELLETT, 2001). During latency FHV-1 is 
most often found in the trigeminal ganglion (REUBEL ET AL., 1993).  
The ability of FHV-1 to establish a lifelong latent infection in cats is similar to that 
of HSV-1 in humans: following primary infection of epithelial cells HSV is 
transported retrograde along the sensory neuron axons and into the cell body 
within a ganglion, where the virus either replicates or establishes latency 
(PENFOLD ET AL., 1994; ROIZMAN AND KNIPE, 2001). LYCKE and co-investigators 
(1988) described the transportation of HSV-1 along the cytoskeleton in sensory 
neurons against the neuronal stream. Upon neuronal damage or activation, the 
virus is periodically reactivated and becomes infectious again. Most often capsids 
are transported anterograde back into the epithelial tissue, were the reactivation 
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may be asymptomatic or may result in a recurrent lesion associated with virus 
shedding (ROIZMAN AND KNIPE, 2001).  
 
 
2.1.3. Replication Cycle 
The replication of HSV-1 has been studied extensively and most other known 
alphaherpesviruses follow a similar pattern. The mechanism of replication is 
categorized as follows: (a) initiation, (b) early gene expression, (c) DNA 
replication, (d) late gene expression, (e) assembly and (f) release (NASISSE AND 
WEIGLER, 1997; MURPHY ET AL., 1999; ROIZMAN AND PELLETT, 2001). 
Primary infection with FHV-1 occurs predominantly in epithelial cells of nasal 
mucosa, conjunciva, tonsils and nasal turbinates (CRANDELL AND MAURER, 1958; 
WOLF, 2000). During initiation, multiple proteins participate in the attachment of 
the virus to host cells using cellular receptors. For FHV-1 at least 29 proteins 
have been identified, six of which are glycoproteins in the viral envelope 
(FERGEAUD ET AL., 1984). The three viral envelope glycoproteins, gB, gC and gD, 
have been documented to be essential for HSV-1 infection. (a) The primary 
attachment is initiated by gC and together with gB it binds to glycosaminoglycan 
residues of the cell surface heparan sulfate. To facilitate cellular entry, the third 
envelope protein, gD, binds to a cellular co-receptor (ROIZMAN AND PELLETT, 
2001). In cats, a gD homolog protein named g60 has been described (MAEDA ET 
AL., 1992). Three groups of co-receptors have been found to be crucial for HSV-1 
entry: (a) members of the TNF receptor family, (b) members of the 
immunoglobulin receptor superfamily or the recently documented (c) 3-O-sulfated 
heparan sulfate (SHUKLA ET AL., 1999). Shortly after uncoating of the virion and 
fusion of the envelope with the plasma membrane, viral Fc receptors (gI and gE) 
are expressed on the cell‘s surface and the capsid-tegument structure is released 
into the cytoplasm and transported to the nucleus along the microtubular network 
(SODEIK ET AL., 1997). At the nucleus, the viral genome enters through the 
nuclear pores, where the viral DNA rapidly circularizes into the episomal form 
(MURPHY ET AL., 1999). 
Gene expression of the FHV-1 genome is believed to be similar to the HSV-1 in 
human cells (FENWICK AND ROIZMAN, 1977; FENWICK AND OWEN, 1988). Based on 
viral gene expression, which occurs at different points in time, three classes of 
genes are distinguished: (a) immediate-early (IE, α) genes, (b) early (E, β) genes 
and (c) late (L, γ; partial late γ1- and truly late γ2-) genes. The three classes are 
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transcribed in sequence by host cellular RNA polymerase II and the viral mRNAs 
are translated into IE (α-), E (β-) and L (γ-) proteins (MURPHY ET AL., 1999).  
Early gene expression of FHV-1 occurs within a few minutes after viral infection. 
It is induced by two tegument proteins (VP16 and vhs) that are released into the 
cytoplasm upon entry into the cell. The viral-host-shut-off factor (vhs, exemplified 
by UL41) causes nonspecific degradation of cellular mRNA and shuts off the 
protein biosynthesis in the host cell. To facilitate the initiation process, the second 
tegument protein VP16 (viral protein 16 or α-TIF, trans inducing factor) activates 
together with the cellular transcription factor (Oct1), the transcription of the viral 
immediate early (IE) gene promoter (ROIZMAN AND KNIPE, 2001). By transcription 
of the IE genes, five α-regulatory proteins (ICPO, ICP4, ICP22, ICP27 and 
ICP47) are produced, that stimulate subsequent early gene expression. ICP4 and 
ICP27 initiate and control viral β- or early (E) gene expression and are crucial for 
viral replication and nucleotide metabolism.  
The E gene products (β-proteins) are enzymes that are expressed 4 - 8 hours 
post infection (hpi) and are mainly responsible for viral DNA synthesis. Seven 
proteins are involved in viral DNA replication including thymidine kinase (TK) and 
ribonucleotidreductase, which increase the nucleotide concentration and UL9 
origin-binding protein (OBP/UL9), single-stranded (ss) DNA-binding protein 
(ICP8/UL29), DNA helicase-primase complex (UL5, UL8, UL52), and DNA 
polymerase. Initially, UL9 binds to either the oriL or oriS element of the viral 
genome and begins to unwind the DNA to expose a single-stranded loop-like 
structure. UL9 and ICP8 recruit the DNA helicase-primase complex, which 
unwinds the DNA and synthesizes a primer, from which leading-strand synthesis 
can be accomplished by the viral DNA polymerase holoenzyme. The replication 
then switches to a rolling circle mode and UL9 is released from the DNA. Rolling 
circle replication produces long head-to-tail concatemers of viral DNA, which are 
cleaved into single genome molecules during packaging (ROIZMANN AND KNIPE, 
2001). During the replication and homologous recombination, inverted UL and US-
domains may occur and result in viral isomers of the genome (MURPHY ET AL., 
1999; ROIZMAN AND KNIPE, 2001).  
Following viral DNA-replication the early (β-) proteins promote the expression of 
the late (y-) genes (including ICP5, gB, and gD. The replication is cis-acting and 
requires the viral proteins ICP4, ICP27, and ICP8. The L (y-) genes mainly 
encode viral structural proteins for assembly of progeny viral particles.  
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The initial stages of viral capsid assembly are partially localized in the cytoplasm, 
the final steps occur in the nucleus. Once sufficient amounts of nucleocapsid 
proteins (VP5, VP23 and VP19C), the scaffolding proteins (pre-VP22a and 
VP21), and the viral protease VP24 are present in the nucleus, the scaffolding 
proteins join with VP5. VP5 is found in the form of pentamers and hexamers that 
are linked by VP23 and VP19C triplexes to form the pre-capsid. At this point viral 
DNA can enter the nucleus (ROIZMAN AND KNIPE, 2001).  
The encapsidation of viral concatemers requires a specific terminal sequences. 
The scaffolding proteins are released and the new capsid matures by budding 
through the inner nuclear membrane where the virus obtains proteins and the 
tegument structure. The envelope, which is acquired during the release of 
progeny virus, is most likely obtained from the outer nuclear membrane, but the 
mechanism is not yet fully understood. Either the particles move in vesicles or 
unenveloped through the cytoplasm into the lumen of the endoplasmic reticulum 
(ER), or in vesicles through the Golgi network where final maturation of the virion 
glycoproteins occurs. Finally, progeny virus is released through the plasma cell 
into the extracellular space. In addition to traveling through the intercellular 
space, progeny virus can spread from cell to cell across cell junctions (ROIZMAN 
AND KNIPE, 2001). Tissue damage during active FHV-1 infection is due to viral 
cytopathogenic properties and occurs after progeny virus is released (CRANDELL 
AND DESPEAUX, 1959; CRANDELL, 1973, CRANDELL ET AL., 1973).  
 
2.2. Feline Herpesvirus Disease 
2.2.1. Epidemiology and Pathogenesis 
Feline herpesvirus-1 (FHV-1), also known as feline rhinotracheitis virus (FVR), 
has a world wide distribution in the cat population. The incidence in colony cats is 
high (> 70 %) compared to the incidence in single-cat households (< 50 %) 
(MURPHY ET AL., 1999). The virus was first isolated from a cat suffering from feline 
viral rhinotracheitis (FVR) (CRANDELL AND MAURER, 1958).  
The enveloped virion is relatively fragile and very susceptible to heat, drying or 
disinfectants. It can persist in the environment at room temperature for only about 
24 hours in relatively dry conditions (POVEY, 1979; BALDWIN, 1992; HARTMANN, 
2000). Low humidity and good disinfection (i.e. household bleach) are 
preventative measures for the control of the virus (BALDWIN, 1992). 
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Antigenic similarities within isolated viruses indicate that all strains belong to one 
serotype (HORIMOTO ET AL., 1992; GASKELL AND DAWSON, 1998) and appear to be 
restricted to domestic and wild felids (SCHERBA ET AL., 1988; HOFMANN-LEHMANN 
ET AL., 1996). Together with feline calicivirus (FCV), FHV-1 is recognized as the 
major cause (> 90 %) of feline upper respiratory infections in cats (GASKELL AND 
DAWSON, 1998; HARTMANN, 2000). FHV-1 is highly contagious and besides the 
individual susceptibility, major environmental risk factors for infection include 
population density (crowding), the intensity of viral exposure and the virulence of 
the virus strain (GASKELL AND DAWSON, 1998). Kittens from the age of four to six 
weeks to the age of twelve months are particularly susceptible to FHV-1 infection, 
as are immune suppressed adult cats (e.g. lactating cats). Cats with underlying 
disease (e.g. feline leukemia virus; feline immunodeficiency virus) are also very 
susceptible to FHV-1 (NASISSE, ET AL., 1993).  
FHV-1 infection can manifest as an acute or chronic infection after which over   
80 % of infected cats are unable to eliminate the virus and become latent carriers 
(GASKELL AND DAWSON, 1998). FHV-1 has been isolated mainly from trigeminal 
ganglion in latently infected cats (GASKELL AND POVEY, 1979; GASKELL ET AL., 
1985; NASISSE ET AL., 1992). Thus, the virus persists in the cat population and 
infectious, latent and chronic carriers serve as a source of infection (WOLF, 2000).  
FHV-1 infection is mainly acquired by mucosal contact with virus containing 
secretions and excretions from virus shedding cats (GASKELL AND POVEY, 1982; 
GASKELL AND DAWSON, 1998; WOLF, 2000). The virus enters the host 
predominantly through oronasal or conjunctival routes and preferentially 
replicates at temperatures slightly below 37°C. As a result, the infection most 
often remains localized in superficial epithelial tissue (WOLF, 2000; HARTMANN, 
2000) and this may include the corneal epithelium (NASISSE ET AL., 1989A). 
Vertical transmission can occur and result in abortion, but more often kittens 
become infected when their maternal derived antibodies wane (WOLF, 2000). 
Death and wasting illness during the early perinatal period may also be observed, 
but are considered a result of debilitation from the disease (BALDWIN, 1992). 
 
2.2.2. Systemic Manifestation 
Typical features of FHV-1 infection include upper respiratory tract symptoms, 
ocular manifestations and reproductive failure (WOLF, 2000). The acute disease 
manifests more severely in kittens than in adult cats. After an incubation period of 
about 24 - 48 hours, a sudden onset of paroxysmal sneezing, followed by profuse 
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serous nasal and ocular discharge, hypersalivation, fever, anorexia and lethargy 
may be observed (CRANDELL ET AL., 1958, BALDWIN, 1992; MURPHY ET AL., 1999; 
WOLF, 2000). Titers of acutely infected animals are high and nasal and ocular 
discharges contain large amounts of virus for up to two weeks post infection 
(BALDWIN, 1992; WOLF, 2000). The discharge may progress from serous to 
mucopurulent due to bacterial invasion (WOLF, 2000). Commonly, these 
symptoms are associated with keratitis, punctuate corneal ulcers and mild 
conjunctivitis (GASKELL AND DAWSON 1998; WOLF, 2000).  
Coughing and dyspnoe frequently seem to be associated with secondary 
Bordetella bronchiseptica infection (WELSH, 1996). Oral ulceration and excessive 
salivation are rare observations with FHV-1 infections but are commonly 
associated with FCV (WOLF, 2000). 
In most cases, primary FHV-1 infection is self-limiting and symptoms regress 
within 10 - 14 days (GASKELL AND DAWSON, 1998). Almost every cat develops a 
chronic or latent carrier state post primary infection and virus shedding may result 
in recurrence of symptoms or remain asymptomatic for lifetime. In chronic 
disease, clinical symptoms may follow a waxing and waning cycle and may be 
less severe than during the acute course of the disease. Recurrence of the 
disease and episodes of viral shedding are often triggered by stress and can be 
experimentally induced by corticosteroid treatment (GASKELL AND POVEY, 1973; 
GASKELL AND POVEY, 1977; WOLF, 2000). Chronic sinusitis and bacterial overgrow 
may follow severe primary infection and may result in necrosis and distortion of 
the turbinates (GASKELL AND POVEY, 1977; GASKELL AND DAWSON, 1998). 
Superficial cutaneous ulceration can occur occasionally, and ulcerative, 
necrotizing facial dermatitis or stomatitis have been associated with FHV-1 
infections in cats (HARGIS AND GINN, 1999; SCOTT ET AL., 2001).  
Viremia, generalized systemic infections, and manifestation in abdominal organs 
and the central nervous system (GASKELL AND POVEY, 1979; WOLF, 2000). In 
experimentally infected cats characteristic, histopathological findings are 
inclusion bodies with halos (Cowdry A-type), and inflammatory infiltration of the 
epithelial tissue (LAVACH ET AL., 1977; GRACIA-KENNEDY, 1998).  
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2.2.3. Ocular Manifestation 
FHV-1 is considered one of the most important ocular pathogens in feline 
ophthalmology. It is the most frequently encountered cause of conjunctivitis and 
keratitis in cats (GLAZE AND GELATT, 1991; STILES, 2000; ANDREW, 2001). There is 
evidence of FHV-1 involvement in the development of symblepharon, proliferative 
keratoconjunctivitis (eosinophilic keratitis), keratoconjunctivitis sicca (KCS) and 
corneal sequestration (BISTNER ET AL., 1971; SPIESS, 1985; CHADIEU AND FONCK, 
1989; NASISSE ET AL., 1998). The ocular symptoms result from viral cytopathic 
effects (CPE) in infected epithelial tissue and secondary bacterial invasion. 
Particularly in adult cats, symptoms may or may not be associated with signs of 
upper respiratory infection (NASISSE ET AL., 1989A; NASISSE AND WEIGLER, 1997). 
Ophthalmia neonatorum may be associated with FHV-1 infection (GLAZE AND 
GELATT, 1991), and the participation of FHV-1 has been suspected in uveitis 
anterior (MAGGS ET AL., 1999A).  
FHV-1 replicates in the conjunctiva and to some degree, in corneal epithelium 
(NASISSE ET AL., 1989A). Corneal lesions occur in a biphasic pattern in relation to 
virus replication and release of progeny virus (NASISSE AND WEIGLER, 1997). The 
pathogenesis of FHV-1-induced stromal keratitis is similar to naturally occurring 
HSV-1 keratitis in humans. While corneal ulceration is directly related to the 
cytopathic effect of FHV-1 replication in cells, stromal keratitis may develop as a 
result of the immune response to the viral antigen inducing stromal damage due 
to recruited cytotoxic T-Lymphocytes (NASISSE, 1995). 
Apart from trigeminal ganglia, FHV-1 has been isolated from corneal tissue of 
chronic carriers (GASKELL AND POVEY, 1979; NASISSE ET AL., 1992). FHV-1 can be 
activated by corticosteroid therapy or endogenous and exogenous stress factors 
(GASKELL AND POVEY, 1977; NASISSE ET AL., 1989A; SLATTER, 2001) resulting in 
recurrence of virus replication, progressive stromal keratitis, geographic lesions, 
and/or may result in interstitial edema with deep neovascularization (NASISSE ET 
AL., 1989A). 
Acute primary ocular FHV-1 infection usually consists of severe bilateral 
conjunctivitis in combination with upper respiratory tract infection in neonatal and 
adolescent cats (GLAZE AND GELATT, 1991; ANDREW, 2001). The clinical course of 
the disease may vary considerably and is often associated with other symptoms, 
such as conjunctival hyperemia, corneal ulceration, blepharospasm, chemosis 
and profuse serous to purulent ocular discharge (CRANDELL AND MAURER, 1958; 
BISTNER ET AL., 1971; STILES, 2000). In kittens with severe conjunctivitis, corneal 
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ulceration and fibrinous exudation a symblepharon, resulting in obliteration of the 
lacrimal lake and lacrimal puncta can occasionally develop (BISTNER ET AL., 1971; 
GLAZE AND GELATT, 1991; NASISSE AND WEIGLER, 1997; STILES, 2000). The acute 
disease in immune competent animals is usually self-limiting and resolves within 
10 - 20 days (ANDREW, 2001).  
Approximately four days post primary infection diffuse epithelial necrosis, partial 
loss of the epithelial layer, and a moderate neutrophilic inflammatory response in 
the substantia propria are typical histopathological findings. Inflammation with 
marked polymorphonuclear infiltration and intranuclear inclusion bodies are 
infrequent observations (NASISSE, 1989A AND 1995).  
During acute ocular infection, corneal lesions tend to be microdendritic (delicately 
and diffuse) (GLAZE AND GELATT, 1991); they may occur in a biphasic pattern 
associated with virus replication and spread within the cornea cells (NASISSE AND 
WEIGLER, 1997; STILES, 2000). Early corneal ulcers may also be dendritic (small 
and branching) or geographical (large and irregular), quickly progressing into 
deep corneal ulcers (MARTIN AND STILES, 1998, STILES, 2000). Microdendritic and 
dendritic ulcers are considered pathognomonic for FHV-1 infection (GLAZE AND 
GELATT, 1991; MARTIN AND DIETRICH, 2003). Acute keratitis is usually 
accompanied by mild conjunctivitis, blepharospasm, and serous to mucopurulent 
ocular discharge and hyperemia (NASISSE ET AL., 1989A).  
FHV-1 keratitis is thought to be induced mainly by reactivation of latent virus. 
Therefore, it is primarily observed in adult cats and only occasionally in younger 
cats (GLAZE AND GELATT, 1991; ANDREW, 2001). The ocular infection will 
commonly result in ulcerative keratitis either in one or both eyes in the absence of 
respiratory signs. Corneal ulceration in older cats is likely to recur, heal 
spontaneously or manifest in chronic indolent ulcers resistant to therapy (STILES, 
2000). Recrudescent episodes of virus shedding and corneal epithelial ulceration 
and involvement of corneal stroma may result in fibrosis and scarring and 
subsequently lead to impaired vision or corneal blindness (NASISSE, 1995). Mild 
corneal edema and regions of fibrosis may accompany severe and chronic cases 
and superficial and deep neovascularization might occur (GLAZE AND GELATT, 
1991).  
The role of FHV-1 in the pathogenesis of eosinophilic keratitis or proliferative 
keratoconjunctivitis has been reported: by using polymerase chain reaction 
(PCR), NASISSE and co-investigators (1996B) were able to detect feline 
herpesvirus-1 DNA in 76 % (45/59) of corneal scrapings from cats with 
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eosinophilic keratitis. This disease is unique to the cat and horse and manifests 
as a proliferative, progressive, superficial keratitis (PAULSEN ET AL., 1986). The 
initial clinical observations include uni- or bilateral, progressive, reddish, pink 
granulation tissue usually arising from either the temporal or nasal limbus and 
progressing into a bilateral keratitis covering the whole cornea. In chronic cases, 
pinkish white deposits of cheesy consistency rich in eosinophilic granulocytes are 
present (MARTIN AND STILES, 1998). Tear production may be decreased and 
blepharospasm is present in about 20 % of cases. The conjunctiva and the third 
eyelid may be severely implicated as well as adjacent corneal tissue (ALLGOEWER 
ET AL., 2001). Histopathological findings in proliferative keratitis are chronic 
granulomatous inflammation characterized by infiltration of plasma cells, 
lymphocytes, numerous eosinophilic granulocytes and occasionally mast cells 
(GLAZE AND GELATT, 1991; PRASSE AND WINSTON, 1996). 
Recently published data also reveals FHV-1 involvement in corneal sequestrum, 
another unique problem to the cat (NASISSE ET AL., 1998). Corneal sequestrum is 
also known as necrotizing keratitis, partial mummification, focal degeneration with 
sequestration, or feline keratitis nigrum and appears on the cornea as a brown-
black plaque of unknown etiology (SOURI, 1975; PEIFFER AND GELATT 1976; 
VAWER, 1981; BLOGG ET AL., 1989; MORGAN, 1994; SLATTER, 2001). The isolated 
black lesions commonly develop over several months by degeneration of 
collagen and accumulation of brown pigmentation (KNECHT AND SCHILLER, 1966; 
GELATT, 1971; SOURI, 1975; VARWER, 1981). Particularly prone to corneal 
sequestra are Persian, Himalayan, Burmese (GELATT ET AL., 1973), Siamese, and 
American domestic shorthair cats. This partial breed disposition suggests a 
genetic basis for the disease (CHAUDIEU AND FONCK, 1989). Corneal sequestrum 
is occasionally accompanied by entropion, blepharospasm, trichiasis, keratopathy 
or keratoconjunctivitis sicca (GELATT ET AL., 1973). A causal connection between 
corneal sequestration and FHV-1 infection is suspected as FHV-1 was detected 
by polymerase chain reaction (GELATT ET AL., 1973; NASISSE ET AL., 1998). In the 
histological examination, the sequestrum consists of stromal desiccation and 
degeneration neighbored by a zone of mononuclear inflammatory cells including 
lymphocytes, plasma cells, macrophages and, to a lesser degree, neutrophils 
and giant cells (GELATT ET AL., 1973). 
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2.2.4. Diagnosis 
Primary FHV-1 infection is suspected when characteristic ocular and respiratory 
signs as described above are observed. However, the only pathognomonic 
clinical sign during primary infection is the presence of dendritic corneal ulcers 
(ROBERTS ET AL., 1972). These can be detected by staining with rose bengal 
(GLAZE AND GELATT, 1991; NASISSE AND WEIGLER, 1997). As chronic and 
recrudescent FHV-1 infection in adult cats most often occur without respiratory 
involvement, the clinical diagnosis is more or less presumptive. Dendritic herpes 
keratitis may be present inconsistently (ROBERTS, 1972).  
For the laboratory diagnosis of FHV-1 infection, a number of assays are 
available. The most frequently used detection methods are the 
immunofluorescent antibody assay (IFA) (CARLSON AND SCOTT, 1978) and virus 
isolation (VI) (MAGGS ET AL., 1999B). IFA can either be performed as a direct test 
(polyclonal fluorescein conjugated antibody) or an indirect test (polyclonal 
unlabled antibody, that is then reacted with a conjugated antibody). A 
disadvantage of IFA is its low sensitivity (NASISSE AND WEIGLER, 1997). Samples 
for IFA should be taken before the eye is stained with fluorescein to avoid false 
positive fluorescence. This does not occur when tetramethylrhodamine 
isothiocyanate (TMRC)-conjugates is used instead of fluorescein isothiocyanate 
(FITC)-conjugates (DA SILVA CURIEAL ET AL., 1991).  
Virus isolation (VI), formerly considered the “gold standard”, is indicated when 
multiple cats show typical symptoms. The sensitivity of this method is influenced 
by handling techniques and the method is more time-consuming than other 
diagnostic techniques and should be performed by an experienced laboratory. 
The virus is usually grown on CRFK-cells and IFA testing can be used to confirm 
the infectious agent (NASISSE AND WEIGLER, 1997). IFA does not differentiate 
between field virus and attenuated vaccination strain.  
Polymerase chain reaction (PCR) testing is now widely available and has proven 
to be an extremely sensitive method for the detection of FHV-1. Samples for PCR 
testing include conjunctival swabs from the inferior cul de sac, corneal scrapings 
or keratectomy samples. PCR analysis for FHV-1 is based on DNA-amplification 
of the thymidine kinase gene (REUBEL ET AL., 1993; NASISSE AND WEIGLER, 1997). 
PCR and nested PCR (repeated amplification cycles) are highly sensitive for the 
detection of chronic FHV-1 infections (REUBEL ET AL., 1993; NASISSE AND 
WEIGLER, 1997; STILES ET AL., 1997A, B; BURGESSER ET AL., 1999). TOWNSEND 
and co-investigators (2004) recently developed a reverse transcriptase-
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polymerase chain reaction assay to detect feline herpesvirus latency-associated 
transcripts in the trigeminal ganglia and corneas of cats that did not show clinical 
signs. The method is so sensitive that the risk of detecting viral DNA in 
asymptomatic shedding animals is increased (LUTZ ET AL., 1999). 
Cytology for FHV-1 diagnosis may be performed, although it appears to be of 
limited value. Although intranuclear inclusion bodies appear in high numbers 
during primary infections, they are rarely observed as they are hard to identify 
with routinely used stains such as Wright-Giemsa (NASISSE AND WEIGLER, 1997). 
Instead, the May-Grünwald-Giemsa stain has been recommended for identifying 
intranuclear inclusions (BISTNER ET AL., 1971).  
To date, there is no antigen capture ELISA developed for FHV-1, however, a 
commercially available ELISA (Herpchek®: Dupont, Wilmington, DE) for human 
HSV-1 shows 90 % sensitivity and a specificity of 99 % for FHV-1, based on 
comparison with tissue culture isolation (NASISSE AND WEIGLER, 1997). 
Apparently, serum neutralization tests are of limited clinical value as they are 
difficult to interpret due to the high prevalence of vaccinated cats (NASISSE AND 
WEIGLER, 1997; GASKELL AND DAWSON, 1998). 
 
2.2.5. Treatment and Prevention 
Upper respiratory tract infection in the acute stage of the disease is in most cases 
self-limiting. In severe cases systemic administration of antibiotic therapy is 
indicated. The treatment of choice is ampicillin (22 mg/kg q8h) or amoxicillin (22 
mg/kg q8 - q12h). Both antibiotics are very effective, have few adverse side 
effects, and can be given to kittens (HAWKINS, 2003). In cases were Chlamydia 
spp., Bordetella bronchiseptica and Mycoplasma are suspected, the application 
of doxycycline (5 – 10 mg/kg q12h) or chloramphenicol (10 – 15 mg/kg q12h) is 
recommended (WOLF, 2000; HAWKINS, 2003).  
Corneal ulceration requires topical antiviral treatment with Trifluridine (TFT), 
Idoxuridine (IDU), or adenine arabinoside (Ara-A). The treatment protocol should 
consist of five to six treatments per day. The treatment can be continued for 
about two to three weeks at most (HAWKINS, 2003). Trifluridine appears to be the 
most efficient and is the least toxic antiviral agent tested in vitro (NASISSE ET AL., 
1989B).  
Topical treatment with tetracycline or chloramphenicol ophthalmic ointment is 
recommended up to four times daily (WOLF, 2000; HAWKINS, 2003). The use of 
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human interferon has been recommended but IFN dosages seem to vary 
considerably (GOULD, 1998; STILES, 2000) and there is only minimal data 
available to support treatment with human alpha interferon (rHuIFN-α) (FULTON 
AND BURGE, 1985; NASISSE ET AL., 1996A).  
Transient conjunctivitis does not require specific treatment, as it is usually self-
limiting. Treatment with corticosteroids is contraindicated since there is evidence 
that topical corticosteroids can worsen the course of the disease (NASISSE ET AL., 
1989A; HAWKINS, 2003). Hospitalization and conjunctival grafting of severe cases 
with deep ulceration may be indicated (BLOGG, 1989). Treatment with oral           
L-lysine has been reported to be effective against FHV-1 infection at low arginine 
levels when administered during the acute disease in vitro (MAGGS ET AL., 2000). 
However, this treatment is problematic in cats, as a deficiency of arginine may 
result in hyperammonemia, vomitus, ataxia and tetanic convulsions and may lead 
to coma and death (MORRIS AND ROGERS, 1978; ANDERSON ET AL., 1979; BURNS 
ET AL., 1981). Only recently, MAGGS and co-investigators (2003) conducted an in 
vivo study in latently infected cats and reported that a once daily oral 
administration of 400 mg of L-lysine resulted in reduced FHV-1 shedding 
following changes in housing and husbandry but not following corticosteroid 
administration. Apparently, this dose caused only a short-term increase in plasma 
L-lysine concentration but did not alter plasma arginine concentration or induce 
adverse clinical effects. A recent in vitro study has indicated that bovine 
lactoferrin may be of some effect against FHV-1 (BEAUMONT ET AL, 2003).  
The management of chronic upper respiratory tract infection caused by FHV-1 is 
problematic and usually requires treatment for many years. Treatment should 
include topical decongestants to facilitate drainage of secretions, long-term 
antibiotics (amoxicillin, trimetoprim-sulfadiazine) to treat secondary bacterial 
invasion and supportive care (WOLF, 2000; HAWKINS, 2003). In severe cases, 
turbinectomy and frontal sinus ablation might become necessary (HAWKINS, 
2003). Supportive treatment should focus on keeping oronasal pathways clear 
and on frequent removal of ocular and nasal discharge (WOLF, 2000; HAWKINS, 
2003). Cats should be kept in a room with a vaporizer to bring relief, especially 
during episodes of severe congestion (HARTMANN, 2000; HAWKINS, 2003). 
Mechanical breakdown of adhesions is essential to prevent the formation of 
symblepharon. Furthermore, topical povidone-iodine (1 – 4 %) may be beneficial 
but herpetic keratitis may as well be resistant to treatment, and may commonly 
relapse (SLATTER, 2001). 
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Cats with eosinophilic keratitis may respond to corticosteroids, but in cases 
where an association with FHV-1 is suspected, other treatment options should be 
considered instead (MORGAN ET AL., 1996). MARTIN AND DIETRICH (2003) 
recommend oral megestrol acetate, 5 mg/day during the first week and 2.5 - 5 
mg/week maintenance dosage for the following weeks as treatment of 
eosinophilic keratitis. In immune-mediated stromal keratitis, topical cyclosporine 
may improve the clinical signs (MARTIN AND DIETRICH, 2003). 
Vaccination cannot prevent the disease, but may decrease the severity of clinical 
signs. Kittens are usually vaccinated at 8 - 10 weeks, again three to four weeks 
later and finally after another 12 weeks. Booster vaccinations can be given every 
one to three years (HAWKINS, 2003). Subcutaneous and intranasal modified-live 
virus (MLV) vaccines (attenuated) are available, as well as killed (disrupted) virus 
products (JARRETT AND RAMSEY, 2001). The intranasal MLV vaccine provides 
more rapid and superior protection, longer lasting immunity and better 
breakthrough of maternal immunity. It is attenuated to a higher degree than the 
subcutaneous MLV vaccine and has a higher efficacy, but also carries the risk of 
post-vaccinal outbreak of infection. It is neither suitable for immune suppressed 
animals nor for pregnant queens or kittens while maternal immunity persists 
(GREENE, 1998). 
The subcutaneous vaccine produces a slower response and requires at least two 
follow up vaccinations (GREENE, 1998). Modified live vaccines for subcutaneous 
application should not be aerolized in front of the cat and spilled vaccine should 
be washed off, to avoid the risk of virus entry through the oronasal route which 
may cause infection (HAWKINS, 2003). In some cases, it might be useful to 
determine the need for vaccination by analyzing the FHV antibody status in 
serum as it is reported to be prognostic of susceptibility (LAPPIN ET AL., 2002) 
Queens should be vaccinated before breeding. For pregnant queens and also for 
cats with FeLV and FIV infection, the subcutaneous inactivated vaccine is 
reported to be safe, although the protection is much weaker than achieved by 
MLV products (GREENE, 1998; JARRETT AND RAMSEY, 2001). In multiple cat 
households where FHV-1 infection is endemic, management, such as separation 
of kittens and their queens, identification and isolation of carriers, ventilation, < 50 
% humidity and immunity strengthening programs can have a considerable 
influence on the recurrence of FHV-1 infection (JARRETT AND RAMSEY, 2001). 
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2.3. Antiviral Therapy and FHV-1 
A number of antiviral drugs are licensed for the treatment of viral disease in 
humans. Some of those compounds are useful for the treatment of chronic and 
recrudescent FHV-1 disease in cats but in order to be effective a frequent 
administration of the antiviral compound is crucial. As all of the presently 
available antiviral compounds are virostatic and act only during the replicative 
phase of the infection, latent FHV-1 remains unaffected (HEIT AND RIVIERE, 1995; 
GREENE, 1998; CRUMPACKER, 2001).  
 
2.3.1. Nucleoside Analogs 
Idoxuridine (IDU, 5-iodo-2’-deoxyuridine), Trifluridine (TFT, 5-trifluoromethyl-2’-
deoxyuridine), Cytarabine (Ara-C, cytosine arabinoside, 1-ß-D-
arabinofuranosylcyosine), Vidarabine (Ara-A, adenine arabinoside, 9-ß-D-
arabinofuranosyladenine), Ribavirin (Virazole), Acyclovir (ACV, 9-[2-
hydroxyethoxymethyl]guanine) and Ganciclovir (GCV, 9-[1,3-dihydroxy-2-
propoxymethyl]guanine) are nucleoside analogs and act during transcription. 
After an intracellular phosphorylation, they are incorporated into newly 
synthesized mammalian and viral DNA strands. This results in the inhibition of 
viral synthesis but also causes a varying degree of damage to the host (HEIT AND 
RIVIERE, 1995; GREENE, 1998).  
Incorporation of either IDU or its fluorinated compound TFT causes DNA 
breakage and if transcribed, results in defective proteins. As thymidine analogs, 
they are active against DNA-viruses (GREENE AND WATSON, 1998). For both 
compounds, systemic use is precluded as it is associated with significant toxicity 
such as leucopenia, hepatotoxicity, and gastrointestinal problems (HEIT AND 
RIVIERE, 1995; CRUMPACKER, 2001). Apparently, TFT is most effective against 
FHV-1 and has an additional property of better corneal penetration than IDU 
(NASISSE ET AL., 1989B, 1990; HEIT AND RIVIERE, 1995; GREENE, 1998). IDU is 
manufactured as solution and as ointment while in some countries TFT is only 
available as an ointment. Nevertheless, extended topical treatment with either 
drug may cause irritation or therapy resistant corneal ulcers (GREENE, 1998). 
The adenine analog Ara-A and the cytosine analog Ara-C have antiviral efficacy 
against DNA-viruses. After conversion of Ara-C and Ara-A into their triphosphate 
form, they act as competitive inhibitors predominantly of the herpesvirus induced 
DNA polymerase (HEIT AND RIVIERE, 1995). Ara-C and Ara-A are less toxic but 
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also less effective against FHV-1 compared to IDU and TFT (PAVAN-LANGSTON 
AND DOHLMAN, 1972; PAVAN-LANGSTON ET AL., 1973; NASISSE ET AL., 1989B). 
However, their antiviral activity was more effective than that of ACV (NASISSE ET 
AL., 1989B). Administration of Ara-A may prove problematic as it is poorly soluble 
and therefore, it has to be given in large fluid volumes over 12 hours (HEIT AND 
RIVIERE, 1995). 
ACV and GCV are synthetic deoxyguanosine analogs with potent anti-
herpesvirus activity in humans (HEIT AND RIVIERE, 1995). Initially, cellular 
enzymes phosphorylate GCV while ACV requires viral thymidine kinase (TK) 
(2.1.3.) (FYFE ET AL. 1978). Cellular enzymes phosphorylate these compounds 
subsequently into di- and triphosphates. Herpesvirus infected cells contain higher 
concentrations of ACV-TP relative to healthy cells, due to the higher affinity of 
acyclovir for the herpesvirus TK. (HIRSCHBERGER , 1988; HEIT AND RIVIERE, 1995). 
Acyclo-GTP or Ganciclo-GTP competes with deoxyguanosine triphosphate and 
their incorporation into the viral DNA-strand results in the inhibition of viral DNA 
polymerase and termination of elongation (HEIT AND RIVIERE, 1995). 
In contrast to ganciclovir, acyclovir shows little toxicity (reversible obstructive 
nephropathy; local irritation). Side effects of GCV in humans include bone 
marrow suppression, neutropenia, thrombocytopenia, and central nervous signs 
(HEIT AND RIVIERE, 1995; GREENE, 1998). ACV can be administered either 
topically or systemically. In herpesvirus infections in humans, the compound is 
very effective and associated with minor toxic side effects (COLLUM ET AL., 1980; 
MCGILL ET AL., 1981). However, the antiviral activity of ACV against FHV-1 is not 
as effective as it is for other herpesviruses in humans. According to a clinical 
study conducted by NASISSE and co-investigators (1989B), ACV did not reach 
significant efficacious plasma concentration in cats, when given systemically. 
Some FHV-1 strains also showed in vitro-resistance to ACV (WEISS, 1989). ACV-
Dosages recommended for FHV-1 treatment are 25 mg/kg, q12h, PO (HAWKINS, 
2003). The antiviral activity of GCV against most herpesviruses is greater than 
that of ACV, but it is also more toxic. MAGGS and CLARKE (2004) reported an 
equivalent anti-FHV-1 in vitro efficacy for GCV and IDU.  
Valacyclovir hydrochloride (L-valine, 2 [(2-amino-1,6-dihydro-6-oxo-9H-Purin-9-yl) 
methoxy] ethyl ester, monohydrochloride) is the hydrochloride salt of the L-valyl 
ester of acyclovir. It is well absorbed and is rapidly converted to acyclovir, 
resulting in up to fourfold higher acyclovir serum levels compared to oral acyclovir 
administration (JACOBSON, 1993). Histological findings indicate nephrotoxicity, 
and toxic changes in rapidly dividing cell-populations at higher concentrations. 
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Due to its toxic properties, NASISSE and co-investigators considers the drug 
unsuitable for use in cats (1997). 
The triazole purine analog, Ribavirin inhibits the replication of a broad spectrum 
of RNA and DNA viruses, including herpesviruses. It mechanism of antiviral 
action is suggested to occur in numerous ways: Ribavirin 5’monophosphate 
(RMP) indirectly inhibits the synthesis of guanine nucleotides and ribavirin 
triphosphate blocks ATP and GTP binding to RNA polymerase (REYES, 2001). 
Oral and systemic administration may lead to a number of side effects, such as 
extravascular hemolysis, bone marrow suppression, gastrointestinal-toxicity, and 
central nervous symptoms (GREENE AND WATSON, 1998; REYES, 2001;). 
Application by aerosol route reaches only low systemic concentrations. Given 
orally, the concentration in respiratory secretions reaches higher therapeutic 
levels (GREENE AND WATSON, 1998).  
 
2.3.2. Other Compounds 
Foscarnet (PFA) is a pyrophosphate analog with a wide spectrum of antiviral 
efficacy against DNA and RNA viruses. PFA is an inhibitor of the nucleic acid 
polymerase. It acts during transcription but its mechanism is noncompetitive as it 
binds to the pyrophosphate-binding site instead of the base-binding site. PFA 
does not require viral TK and therefore is useful against acyclovir-resistant 
herpesvirus infections (HAWKINS, 2003). MAGGS and CLARKE (2004) investigated 
the antiviral activity of PFA against FHV-1 and reported it to be relatively 
ineffective compared to IDU or GCV. Due to its short half-life, PFA needs 
continuous, intravenous administering in order to be effective. PFA accumulates 
in bone matrix and possibly penetrates the blood-brain barrier. Most of the 
compound’s excretion occurs with the urine, and it is associated with significant 
nephrotoxicity (GREENE AND WATSON, 1998). 
Specific antiviral acting immunoglobulin may prove beneficial in the treatment of 
viral infections, especially when applied early during infection. Administration via 
IM, SC and IP routes are possible, and suitable for puppies and kittens. 
Immunoglobulin can also be given as plasma IV routes (GREENE AND WATSON, 
1998). A beneficial effect of γ-Globuline (Feliserin, Serocat) administration during 
the acute primary infection has not yet been demonstrated. Nevertheless, local 
as well as systemic treatment has been suggested (HARTMANN, 2000). 
Levamisole and Isoprinosine are immune-modulators, which have been used to 
treat viral infections. These compounds have shown promise; however, 
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significant improvement in well-controlled investigations has not yet been 
reported (GREENE AND WATSON, 1998). 
 
2.4. Interferon 
2.4.1. Historical Background 
In 1957, Isaacs and Lindenmann infected cells of the chorioallantoic membrane 
of embryonated hen’s eggs with influenza A-virus and described a nonviral 
protein that was found to render host cells resistant to influenza A-virus as well as 
to other, superinfecting viruses (ISAACS and LINDENMANN, 1957). Although, 
NAGANO and coinvestigators (1954) had described the protein earlier, it was 
named interferon (IFN) by ISAACS and LINDENMANN (1957) due to its viral 
interference. The discovery of Interferon raised hopes for the availability of an 
extraordinarily potent antiviral agent, but as the protein is only present in scarce 
amounts, it took years until it was purified and characterized (KNIGHT, 1976; BERG 
AND HERON, 1980). With advances in molecular cloning techniques and 
recombinant DNA technology, it was finally possible to produce reasonable 
amounts of interferon for further research and therapy purposes. In 1981 several 
human IFN-α (hIFN-α) subtypes were cloned by WECK and co-investigators 
(1981). The cloning of human IFN-β (hIFN-β) (DWORKIN-RASTL ET AL., 1982) and 
murine IFN-γ (m IFN-γ) (GRAY AND GOEDDEL 1983A) followed.  
Human interferons were reported to antiviral efficacy against herpes simplex 
keratitis, either if given alone (NEUMANN-HAEFELIN ET AL., 1975; MCGILL ET AL., 
1976; TROUSDALE ET AL., 1987) or in combination with nucleoside analogs (DE 
KONING ET AL., 1983; SUNDMACHER ET AL., 1984; TAYLOR ET AL., 1991). Topical 
application of interferon early in the course of HSV-1 infection was reported to 
reduce the severity and duration of clinical symptoms (HO, 1990) and to shorten 
the period of virus shedding (SMOLIN ET AL., 1984). 
Some natural and recombinant human and feline IFNs showed antiviral 
properties against selected feline viruses in vitro. HuIFN and/or FeIFN showed 
inhibitory effects against feline leukemia virus (JAMESON AND ESSEX, 1983), 
rHuIFN-αA, rHuIFN-αA/D and a feline IFN preparation (induced in feline lung 
cells, challenged with Newcastle Disease Virus) showed some inhibition of FHV-1 
and FCV (FULTON AND BURGE, 1985; WEISS, 1989). Recombinant HuIFN-α and 
FeIFN-ß were also found to have antiviral activity against feline infectious 
peritonitis (FIP) (WEISS AND TOIVIO-KINNUCAN, 1988; WEISS AND OOSTROM-RAM, 
1990). Further in vitro and in vivo studies investigated the effect of rHuIFN-α in 
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combination with antiviral drugs (CUMMINS ET AL., 1988; WEISS 1989; ZEIDNER ET 
AL. 1990). For FHV-1, WEISS (1989) was able to demonstrate a strong synergistic 
antiviral activity of ACV and a rHuIFN-αA/D hybrid in vitro. These results 
resembled those of a previous clinical study of HSV-1-treatment in humans (DE 
KONING ET AL., 1983).  
In 1985, HAUPTMANN AND SWETLY identified a new and distinct class of 
interferons named HuIFN-ω (HAUPTMANN AND SWETLY, 1985). It is one of the 
more lately characterized interferons (ADOLF, 1995).  
The first recombinant feline interferon (rFeIFN-ω), using a baculovirus-vector, 
was produced in silkworm larvae (UEDA ET AL., 1993A; SAKURAI ET AL., 1992). In 
vivo studies reported that treatment with rFeIFN-ω had some potential against 
parvovirus infection in dogs (ISHIWATA ET AL., 1998; MINAGAWA ET AL., 1999; 
MARTIN ET AL., 2002; DE MARI ET AL., 2003;). Recently, rFeIFN-ω has proven to be 
of some therapeutic value against FIP when used in combination with 
glucocorticoids (ISHIDA ET AL., 2004) 
To date, there are only few in vitro studies available on the anti-FHV-1 activity of 
rFeIFN-ω (MOCHIZUKI ET AL., 1994; TRUYEN ET AL., 2001). MOCHIZUKI and co-
investigators (1994) were able to demonstrate a potential antiviral activity and a 
dose-dependant response of rFeIFN-ω treatments in cell culture. TRUYEN (2001) 
assessed the antiviral effect of 50,000 U/ml of rFeIFN-ω against several canine 
and feline viruses and confirmed a potential antiviral activity of this agent.  
There is one in vivo study, which assessed the pharmacokinetic properties of 
rFeIFN-ω and suggested that its pharmacokinetic properties are comparable to 
those of human interferons (UEDA ET AL., 1993B). The distribution of rFeIFN-ω 
occurred predominantly in the liver and kidneys; it was catabolized mainly in the 
kidneys, and was excreted in the urine. A residual accumulation of rFeIFN-ω in 
the body did not occur. The activity of 2', 5’-oligoadenylate synthetase activity 
was increased by the interferon for 3 days following intravenous application 
(UEDA ET AL., 1993B). A Swiss research group evaluated the biological activity of 
rFeIFN-ω by measuring the Mx-protein-expression following topically and orally 
rFeIFN-ω treatment in cats. A dose-dependent response for the induction of Mx 
proteins and a long-lasting effect was found at high concentrations of rFeIFN-ω 
(BRÄCKLEIN ET AL., 2003). A recent study demonstrated a clinical improvement of 
ocular FHV-1 manifestations when topically treated with high concentrations of 
rFeIFN-ω-treated in vivo (VERNEUIL, 2004).  
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2.4.2. Classification and Properties 
IFNs are glycoproteins that are produced in homologous cells in response to viral 
infection (STEWART ET AL., 1980). They are members of the cytokine family and 
act as important mediators of the initial, innate (nonspecific) and adaptive 
(specific) immune system (BIRON AND SEN, 2001). Apart from antiviral properties, 
IFNs have anti-proliferative and immune modulating properties (ABBAS AND 
LICHTMAN, 2000; BIRON AND SEN, 2001). Initially the IFNs were classified by their 
cellular origin as leukocyte-IFN (now IFN-α), fibroblast-IFN (now IFN-β) and 
lymphocyte-IFN (now IFN-γ). With further advances in IFN research, 
supplementary sources of IFN production were discovered the three major 
classes were classified as IFN-α, IFN-β and IFN-γ (STEWART ET AL., 1980). Based 
on their genetic properties, size and origin, two types of IFNs can be 
distinguished: IFN-α and IFN-β are type I IFNs, while IFN-γ is the only member of 
the type II IFNs (BIRON AND SEN, 2001). Although the type I and type II IFNs are 
structurally distinct and use different receptors (see below), their pathways 
overlap partly, which results in similar biological activities (MOGENSEN ET AL., 
1999; ABBAS AND LICHTMAN, 2003). Type I IFNs are heat and acid stabile, and 
show up to 10-times higher antiviral activity than type II IFNs (FARRER AND 
SCHREIBER, 1993). They are also the most important mediators of the initial and 
innate immune system and can be produced by virtually any cell (BARON, 1996; 
ABBAS AND LICHTMAN, 2003). 
The human IFN-α (HuIFN-α) and human IFN-β (HuIFN-β) have been 
characterized in great detail. A gene family of over 24 genes encodes the genetic 
information for HuIFN-α; HuIFN-β is encoded by one single gene, located on the 
same chromosome. Based on the degree of homology, the gene family for 
HuIFN-α can be further differentiated into: (a) HuIFN-α-1 class with at least 14 
proteins and (b) HuIFN-α-2 class with two proteins (BARON, 1996). The proteins 
consist of about 166 amino acids with molecular weights of about 20 kDa. HuIFN-
α and HuIFN-β genes exhibit significant genome and protein homology (ZOON ET 
AL., 1992). 
Recombinant feline IFN-ω (rFeIFN-ω) has been characterized as a type I IFN on 
the basis of its amino acid identity and classified as an IFN-ω type based on the 
processing pattern of N-terminal sequence (UEDA ET AL. 1993A) and therefore, 
remains unrelated to the three major classes of IFNs (IFN-α, -β, -γ) (ADOLF, 
1995). 
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The type II IFN, IFN-γ is very sensitive to low pH (< 5) and high temperatures (> 
50 °C). It is produced exclusively by immune cells and can mediate a number of 
immunoregulatory functions. IFN-γ is an important member of the adaptive 
immune system, and to a lesser degree than type I IFNs participates in innate 
immunity (BOEHM ET AL., 1997; BIRON AND SEN, 2001). The human IFN-γ (HuIFN-
γ) consists of a homodimer with two identical covalently bound glycosylated 
polypeptidechains, each with 146 amino acids and molecular weights of 20 - 25 
kDa (GRAY AND GOEDDEL 1982, 1983B; NAGATA ET AL., 1987). For the type II IFN, 
only a single IFN-γ gene has been cloned. There is very little sequence homology 
within different species, which indicates the narrow host-species specificity of the 
interferon. 
 
2.4.3. Mechanisms of Antiviral Action 
The most powerful stimulus for the transcriptional activation of type I IFNs is viral 
infection. Specifically, dsRNA, which is expressed during viral replication in 
infected cells (as described in 2.1.3), induces the release of the repressed type I 
genes, and subsequently induces type I IFN synthesis (ABBAS AND LICHTMAN, 
2003). Other stimuli for IFN-α production in mostly dendritic cells include foreign 
cells, tumor cells, bacterial cells, and viral envelopes. IFN-β is induced not only 
by viral, but also by other foreign nucleic acids in most body cells, but mainly 
secreted by fibroblasts, epithelial cells and macrophages. IFN-γ synthesis is 
induced by direct stimulation of T-cell receptors by specific antigens or mitogens 
(MARUCCI ET AL., 1981; BIRON, 1997).  
Upon activation, IFN-γ is produced by thymus-derived T-cells and by natural killer 
(NK) cells (BOCCI ET AL., 1988; BIRON 1997). It can be induced as an initial and 
adaptive response by foreign antigens to which the T-lymphocytes have been 
sensitized. For a successful immune response by IFN-γ, cofactors such as CD-28 
molecules or tumor necrosis factor-α (TNF-α) are required. Simultaneous 
stimulation of T-cell receptor and CD28 induces enhanced proliferation and 
cytokine production of mostly IFN-γ and IL-2, TNF-α. In the regulation of the 
transcriptional activation, several regulatory factors participate by binding to 
specific transcription factors, which are activated by phosphorylation (ABBAS AND 
LICHTMAN, 2003). 
Type I and type II IFNs bind to two different kinds of cell surface receptors. Both 
receptors are members of the type II cytokine receptor family and upon activation 
share components of their signal transduction pathways (FLINT ET AL., 2000; 
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ABBAS AND LICHTMAN, 2003). Receptors for both IFN types are expressed on all 
nucleated cells and receptor numbers vary from 100 - 2000 per cell. Binding of 
the IFN proteins to their receptors occurs with high affinity (FLINT ET AL., 2000; 
BIRON AND SEN, 2001). The cell surface receptor for type I IFNs consists of two 
major polypeptide IFN-type I receptor components (IFNAR1 and IFNAR2c) that 
bind to the cytokine molecule, and associate with the tyrosine kinase (Tyk2) and 
Januskinase (Jak1) (LUTFALLA ET AL., 1995; ABBAS AND LICHTMAN, 2003). The 
type II IFN receptor is also a heterodimer with the major subunits IFN-γ receptor 
(IFNGR1, and IFNGR2). Successful binding of an IFN-γ molecule results in 
binding of Jak1 and Jak2 onto the intracellular domains (BIRON AND SEN, 2001). 
IFN-α, -β and -γ share components of the januskinase/signal transducers and 
share activators of transcription (JAK/STAT-) signal transduction pathway as their 
major signaling cascade (DARNELL ET AL., 1994). Binding on either one of the 
receptors leads to a cascade of tyrosine phosphorylation, of which the following 
are notable: (a) Tyk2 and Jak1 for IFN-α /-β, and Jak1 and Jak2 for IFN-γ 
followed by (b) tyrosine phosphorylation of the signal transducers and activators 
of transcription (STAT1 and STAT2-) proteins for IFN-α /-β and the proteins 
p91/84 for IFN-γ. The phosphorylated STAT proteins form multimeric complexes 
that enter the nucleus and associate with another cellular protein, an interferon 
regulatory factor (IRF-p48/ISGF3), to form defined complexes (KRISHNAN ET AL., 
1996). These complexes can bind to specific transcriptional control sequences of 
IFN-α /-β or IFN-γ inducible genes, called interferon-stimulated response 
elements (ISREs) for IFN-α /-β-inducible genes and IFN-γ-activated site (GAS) 
elements for IFN-γ inducible genes (DARNELL, 1994). 
There are many interferon-independent pathways in cells that can be activated 
following expression of viral dsRNA in the infected cell. These pathways are not 
yet fully understood. However, the dsRNA signals are received by ISREs evading 
the Jak/STAT factors and a dsRNA-activated factor (DRAF) or virus-activated 
factor (VAF) binds to the ISRE. As a result, target gene transcription is activated 
and the responding cells release the produced interferons (FLINT ET AL., 2000). 
The most important antiviral action is induced on the site of infection by newly 
released type I IFNs that successfully bind to surface receptors of cells, which are 
not yet infected. The type I IFNs do not inactivate the virus directly, but instead 
interfere by up regulating the expression of antiviral effector-proteins which can 
lead to innate immunity of the cell (FLINT ET AL., 2000). One of the numerous 
effector-proteins induced is the inactive proenzyme protein kinase, which requires 
viral dsRNA or another cellular protein for its activation by autophosphorylation 
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(CARPICK ET AL., 1997). The dsRNA-activated protein kinase (PKR) can 
phosphorylate the eukaryotic protein-synthesis-initiation factor (eIF2α) to inhibit 
protein synthesis. The type I IFNs also induce the 2’,5’-oligoadenylate-
synthetase, which is activated by viral dsRNA to synthetize 2-5-linked 
oligoadenylates which in turn activates the RNase L. The concentration of RNase 
L increases 10 – 1000 fold after IFN treatment and degrades most cellular and 
viral RNA species. Thereby, it inhibits protein synthesis and the replication of 
virus in the cell (FLINT ET AL., 2000, BIRON AND SEN, 2001). 
Besides these broad spectrum antiviral effects of PKR and RNase-L, the Mx 
proteins and other guanylate binding proteins have been shown to inhibit specific 
RNA viruses in humans by interaction with viral nucleocapsids, but their antiviral 
mechanisms are not yet fully understood (HORISBERGER, 1992; HALLER ET AL., 
1998; BIRON AND SEN, 2001). In addition, Type I IFNs induce antiviral responses 
by enhancing cytolytic activity of NK cells before adaptive immune responses 
have developed, and by increasing the expression of class I MHC molecules. 
This facilitates the development of adaptive T-cell responses (TNF-α) (BIRON AND 
SEN, 2001; ABBAS AND LICHTMAN, 2003). Important IFN-γ inducted antiviral 
activities include the production of nitric oxide synthase. This has a variety of 
effects including inhibition of herpesvirus replication (BIRON AND SEN, 2001). 
Prolonged activity of IFN-induced proteins and all the above-mentioned 
mechanisms lead to cell death, which inevitably results in a limited spread of 
progeny virus from cell to cell (FLINT ET AL., 2000). 
 
2.4.4. Availability and Medical Application 
In human medicine, interferons have been approved in several countries for the 
treatment of viral infections and cancer. The currently human-approved IFNs in 
Europe and the United States are human recombinant IFN-α2a (Roferon®-A) and 
IFN-α2b (Intron® A). Roferon-A® and Intron®A in humans are licensed for the 
usage in Hairy Cell Leukemia, Malignant Melanoma, Follicular Lymphoma, 
Condylomata Acuminata, AIDS-related Kaposi’s sarcoma, and Chronic Hepatitis 
C and B (STUART-HARRIS ET AL., 1992; MANUFACTURERS DRUG INFORMATION). 
Routinely used application methods for IFNs include intramuscular, 
subcutaneous and intralesional injections, as well as topical administration 
(CANTELL and PYHALA, 1976). In addition, IFN-β has received US governmental 
approval for treatment of relapsing multiple sclerosis (BARON, 1996). 
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The U.S. Food and Drug Administration (FDA, available from: 
URL:http://www.fda.org) has not yet approved human IFNs in veterinary 
medicine. Nonetheless, Roferon®-A has been used in cats for the treatment of 
non-neoplastic, FeLV-disease. For the treatment of non-neoplastic FeLV-
associated disease and ocular lesions, oral administration has been suggested 
(CUMMINS, 1988). The recommended dosage for rHIFN-α (Intron® A) is 30 IU/ml, 
q12h, PO. The dosage can be increased in life threatening viral infection to up to 
10,000 IU/ml- 20,000 IU/kg in cats (HAWKINS, 2003). rFeIFN-ω (Virbagen® 
Omega) has recently become available for use in animals in Europe 
(EMEA/V/C/061/01-02/00/00; EUROPEAN COMMISSION - ENTERPRISE DG - 
PHARMACEUTICALS: REGULATORY FRAMEWORK AND MARKET AUTHORIZATIONS, NOV. 
6, 2001. Available from: URL:http://pharmacos.eudra.org). Virbagen® Omega is 
approved for veterinary usage in parvovirosis in dogs. The recommended 
application and dosage is once a day for 3 consecutive days at 5 - 10 MU/ml IV 
(MANUFACTURERS DRUG INFORMATION).  
 
2.5. Purpose and Design of Study 
The use of rHuIFN-α has been recommended for the treatment of feline 
herpesvirus infection (GOULD, 1998; STILES, 2000). However, at the present time 
there is only minimal data available to justify this treatment (FULTON AND BURGE, 
1985; NASISSE ET AL., 1996A; WEISS, 1989). Before recombinant feline interferon 
was available, interferons could only be produced in scarce amounts, were of 
different sources and purity (FULTON AND BURGE, 1985). Recently, the first 
recombinant feline type I interferon (rFeIFN-ω) was produced in silkworm larvae 
(SAKURAI ET AL., 1992; UEDA ET AL., 1993A) using a baculovirus vector, and has 
become commercially available (SAKURAI ET AL., 1992). Initial studies have 
assessed the antiviral properties of rFeIFN-ω against canine and feline virus 
infections (MOCHIZUKI ET AL., 1994, TRUYEN ET AL., 2001) and reported promising 
in vitro effects of rFeIFN-ω against FHV-1 infection. MOCHIZUKI and co-
investigators (1994) assessed its antiviral activity at 100 U/ml and 1,000 U/ml and 
TRUYEN and co-investigators (2001) evaluated the anti-FHV-1 effect at 50,000 
U/ml.  
It was the purpose of this study to evaluate and compare the antiviral efficacy of 
the recently available feline rFeIFN-ω (Virbagen®-ω) and a human rHuIFN-α 
(rHuIFN-α2b; Intron®-A) in CRFK-cells against FHV-1 infection in vitro. A wider 
range of concentrations (100 U/ml - 500,000 U/ml) was studied than used in the 
previous studies of MOCHIZUKI et al. and of TRUYEN et al. mentioned above in 
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order to repeat the previously tested concentration. Further, as IFN dosages 
recommended for the use in cats seem to vary considerably (GOULD, 1998; 
STILES, 2000) this range was chosen to determine whether the drugs have a 
dose-dependant response of antiviral activity and which concentration would be 
the most effective treatment dosage. The species-specificity of type I interferons 
is well known and therefore, rFeIFN-ω would be expected to result in a more 
profound antiviral effect than the rHuIFN-α2b due to its homologous nature in the 
feline cell line. 
The choice of the cell and virus culture system is always a compromise between 
the ability of the virus to grow adequately and the drug tolerance of the cells. 
Previous work has established that CRFK-cells are relatively easy to propagate 
and are susceptible to FHV-1 (CRANDELL ET AL., 1973; THAM AND STUDDERT, 
1985): the virus strain multiplies well in CRFK-cells and produces distinct 
cytopathic effects (CPEs) and well-defined plaques (CRANDELL AND MAURER, 
1958, CRANDELL AND DESPEAUX, 1959). The above suggests that the           
CRFK-cell/ FHV-1-system is an ideal virus-cell-culture system to evaluate 
antiviral activity by plaque reduction assay.  
The plaque reduction assay (PRA) has been the accepted method of antiviral 
susceptibility testing ever since Renato Dulbecco introduced it for the use in 
animal virology in 1952 (FLINT ET AL., 2000). The principle of the method is based 
on visualizing the antiviral effect microscopically by the suppression of viral 
plaque formation in the presence of an antiviral agent. Under optimal conditions, 
i.e. when the virus is distributed evenly and progeny virus is limited to cell-bound 
spread by a solid overlay, one single plaque results from a single-infectious 
virion. Thereby the method allows the direct quantification of the antiviral impact 
of the compound against the infection in vitro (SWIERKOSZ AND BIRON, 1995; FLINT 
ET AL., 2000).  
In previous studies, the virus-yield reduction assay has been used for testing the 
effect of interferon on FHV-1 replication (MOCHIZUKI ET AL., 1994; TRUYEN ET AL., 
2001). The virus-yield reduction assay consists of two virus culture episodes. In 
the first episode, virus-infected cells (high MOI) are exposed to the antiviral 
compound over a period of 2-3 days. Virus-containing supernatants are 
subsequently collected and frozen. In the second culture episode, the plaque 
number is quantified and titers are compared to titers of virus control wells 
(VOGEL ET AL., 1991). The plaque reduction assay has the advantage that the 
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procedure is of shorter duration, and an antiviral effect can be directly observed 
in cell cultures in the presence of the test-compound.  
An in vitro MTT-Assay was integrated in the experiment as a control to exclude 
possible cytotoxic effects that could, in principle, contribute to the antiviral effect 
observed following treatment with either of the two interferons. The MTT-Assay is 
a rapid method for the detection of a potential cytotoxic effect of a compound on 
a cell culture (MOSMANN, 1983). To improve the procedure, a standardized plate 
layout was used. An internal standard on the plate (alive control) and a control 
with known performance (dead control) were used to validate each individual 
plate.  
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3. Materials and Methods 
3.1. Materials 
All Materials were handled in accordance with the legal requirements for 
Biosafety Level II Agents in the United States (available from 
URL:www.cdc.gov/). A list of cell culture media and reagents used in this study is 
included in the appendix (section 9).  
 
 
3.1.1. Cell Line 
Crandell feline kidney (CRFK)-cells were purchased (1 ml frozen cell suspension 
of 1.9 x 106 cells/ml, in 95 % DMEM and 5 % DMSO), from American Type 
Culture Collection (ATCC, Manassas, VA, USA. Available through: 
URL:http://www.atcc.org). The cells were originally derived from feline kidney 
cortex and propagated as a continuous cell line. CRFK-cells are epithelial-like 
cells; they adhere to cell culture treated surfaces and form monolayers. The 
purchased strain was provided free of BVD-virus, mycoplasma, bacteria and 
fungi.  
 
 
3.1.2. Virus Strain 
Feline herpesvirus-1 (FHV-1) strain C-27, (1 ml freeze-dried virus, reconstituted 
to the original volume of an approximate titer of 105.95 TCID[50]/ml) was obtained 
from ATCC. The virus was originally isolated from throat and conjunctival swabs 
of a cat with respiratory infection. FHV-1 causes cytopathic effects and 
intranuclear inclusions in CRFK-cell culture and it induces the formation of 
mineral crystals in CRFK-cells (CRANDELL ET AL., 1973). 
 
 
3.1.3. Interferon 
Recombinant human Interferon-α2b (rHuIFN-α2b; Intron®-A) was obtained from 
Schering-Plough (Schering Corporation, Kenilworth, NJ, USA. Available from 
URL:http://www.schering-plough.com) as a lyophilized preparation (Lot Nr. 2 IFD 
303). Each vial contained a powder fraction of10 MU per ml and was diluted in 
isotonic sodium chloride solution. The original stock solution was stored at 2 - 
4°C and a working stock of 5 MU per ml was prepared just before use. 
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Recombinant feline Interferon-ω (rFeIFN-ω; Virbagen® Omega.) was donated by 
Virbac SA (Virbac SA, Carros, France. Available from: URL:http//www.virbac.fr). 
It was received as a lyophilized preparation (Lot Nr. WI22). Each vial contained a 
powder fraction, which was dissolved in isotonic sodium chloride solution to a 
final concentration of 10 MU per ml. The original stock solution was stored at 2 - 
4°C and a working stock of 5 MU per ml was prepared just before use.  
 
 
 
3.2. Cell and Virus Culture Methods 
All cell culture work was performed in a Biosafety Cabinet II. During incubation 
periods, the cells were placed in a controlled, humidified (98 %) incubator (37 °C 
and 5 % CO2 /95 % O2. 
 
 
3.2.1. Cell Bank 
The original CRFK-cell stock contained approximately 1.9 x 106 cells per ml. Over 
several passages, the original cell stock was extended; aliquots were frozen and 
stored in liquid nitrogen until a representative master cell stock (80 vials, 
passages 7 and 8) was established and frozen. From the master cell stock, 
passages were repeatedly cultured as required until sufficient amounts of    
CRFK-cells were gained to conduct the experiments (passages Nr. 9 – 12). 
These passages were used as working cell stock throughout the following cell 
culture procedures and experiments.  
 
 
3.2.2. Propagation of Cells 
CRFK-cells were seeded and cultured in tissue culture flasks (Easy Flask, 
Nunclon™∆ 75 cm2 (T-75) and Corning Flask, w/v vented cap 25 cm2 (T-25)) 
containing growth medium (D-MEM, high glucose containing 10 % FBS,          
100 µg/ml Penicillin, 100 U/ml Streptomycin, 2.5 µg/ml Amphotericin B). The 
epithelial cells attached to the surface, flattened, grew, split rapidly and formed a 
confluent sheet of cells (approx. density 8.45 x 106 cells per T-75).  
The cell cultures were generally split either at or near confluency. To 
disaggregate cells from each other and detach them from the flask’s surface, the 
growth medium was replaced by a Trypsin-EDTA Solution (0.03 % w/v Trypsin, 
0.25 % w/v EDTA). The flasks were placed in the incubator to facilitate the 
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dispersal of the solution. When the cells became spherical and lifted off the flask 
surface, twice the volume of growth medium was added to terminate the 
proteolysis. The cell suspension was collected and centrifuged at 800 × g for  
5 minutes to remove the residual dissociation solution. The supernatant was 
decanted and the cell pellet suspended in growth medium pre-warmed to 37 °C. 
A sample was taken from this suspension and a cell count and a viability stain 
were performed (as described in 3.2.4.3.). The split ratio was calculated (either 
1:2, 1:3 or 1:5) and the suspension extended to an appropriate volume (see 
Table 3.1). 
 
Table 3.1. Seeding densities and volume requirements for cell culture 
propagation 
CELL CULTURE VESSEL SURFACE 
AREA 
(cm2) 
SEEDING DENSITY 
cells/ml 
GROWTH 
MEDIA 
ml 
TRYPSIN-EDTA 
ml 
CORNING FLASK, STERILE;  
W/V VENTED CAP 25 CM2,  
VWR CAT.# 29186-010 
25 0.8 x 106 5 ml 1.5ml 
EASY FLASK, STERILE;  
NUNCLON™∆ 75 CM2,  
VWR CAT.# 15708-134 
75 2.6 x 106 10 ml 3 ml 
BD FALCON, 24-WELL CULTURE 
PLATES WITH LIDS, STERILE, 
TISSUE CULTURE TREATED. 
VWR# 62406-183 
2 0.5 x 106 1 ml* -/- 
BD FALCON, 96-WELL CULTURE 
PLATES WITH LIDS, STERILE  
TISSUE CULTURE TREATED,  
VWR# 62406-070 
1 0.74 x 106 200 µ* -/- 
*volume per well 
 
3.2.3. Cryopreservation 
After Trypsin-EDTA treatment (as described in 3.2.2.) the cells were collected, 
pooled and centrifuged at 800 × g for 5 minutes. The supernatant was decanted 
and the pellet suspended in an estimated amount of prepared storage medium 
(D-MEM, containing 10 % DMSO and 20 % FBS). A cell count was performed (as 
described in 3.2.4.3.) and the volume extended to a concentration of 
approximately 2 x 106 cells per ml. One-ml aliquots were dispensed into 
cryogenic vials, marked and transferred into an incremental cooling device      
(“Mr. Frosty”, Sigma Cat. # C1562) and placed into a -80 °C Freezer for 24 hrs. 
For long term preservation the vials were transferred to a nitrogen tank where 
they were stored in the vapor phase (-156 °C) until they were needed and 
resuscitated. When needed for culture, the cryovials were removed from the 
nitrogen tank and placed in a water bath at 37 °C. Under rapid agitation of the 
vial, the frozen cell suspension was thawed within 40 to 60 seconds. The outside 
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surfaces of the vials were disinfected and aseptically transferred into the hood 
where the cells were then dispensed at an approximate seeding density of          
1 x 106 cells per T-25 flask in 5 ml of growth medium and incubated at 37 °C and 
5 % CO2/95 %O2. 
 
 
 
3.2.4. Quality Assurance 
3.2.4.1. Microscopic Evaluation 
The cultures were examined daily in order to detect contamination (change of 
color in the medium, bacteria, fungi) and observe the growth, morphology and 
density of the cells using an inverted microscope (microscopic magnification        
x 100 – x 400). When contamination of a passage was suspected, cultures were 
discharged and new passages were resuscitated from the master cell stock and 
used. 
 
 
3.2.4.2. Recovery of Frozen Cell Stock 
Every one to two weeks after cells had been frozen and stored in liquid nitrogen, 
one vial of the frozen stock was thawed and the cells were seeded (dilution 
determined by the concentration of viable cells present at freezing) and observed 
concerning the recovery time and viability of cells in the culture.   
 
 
3.2.4.3. Quantification and Viability 
Cell viability was assessed by trypan blue exclusion (Gibco, Cat. # 15250-012, 
trypan working solution 0.03 % w/v) on a routine basis when the cell cultures 
were split. The concentration of the cell suspension (collected as described in 
3.2.2.) was determined by counting cells (initial dilution 1:10) of a known volume 
and within a defined area (10 squares holding a volume of 1.0 x 10-3 ml) using an 
improved Neubauer hemocytometer (0.1 mm deep) and at a microscope 
magnification of 100 x. By trypan blue exclusion it was possible to estimate the 
viability of cells in the dilutions. Stained (dead) and unstained (living, intact) cells 
were counted separately. If the initial dilution resulted in more than 50 cells per 
square, further dilutions were prepared to improve counting accuracy.  
 
The concentration of the cell suspension per ml is calculated as follows: 
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Total number of cells/ml = total number of cell counted in 10 squares x dilution 
factor x 1000 
 
 
                       % VIABLE CELLS =             VIABLE CELLS (UNSTAINED) 
                           [VIABLE CELLS+ DEAD CELLS (STAINED)]   
 
X 100   
 
 
 
 
3.2.4.4. Growth Rate and Doubling Time 
To determine the doubling time of the cell culture, a cell suspension was 
collected (as described in 3.2.2.) and diluted in growth medium at two different 
concentrations (15 ml 1 x 105 cells/ml and 15 ml of 5 x 104 cells/ml). The cells 
were seeded into 24-well plates at one ml per well and incubated. After 24 hrs, 
the medium of two wells of each dilution was removed, the cells trypsinized 
(described in 3.2.2.) and an aliquot of each well was diluted 1:10 in trypan blue 
(working solution) and counted using a hemocytometer. This procedure was 
repeated over six days and samples were taken at 24 hour intervals. The mean 
cell counts were plotted against the elapsed time and the doubling time was 
estimated. The number of population doublings was determined as follows: 
 
Number of population doublings = 10 Log (N/N0) 
N = Number of cells in growth vessel at end of a period of growth 
N0 = Number of cells plated in the growth vessel 
 
 
3.2.5. Virus Bank  
To standardize the virus stock and secure a constant titer the original freeze dried 
FHV-1 powder fraction was diluted in 5 ml of phosphate buffered saline (PBS) 
and split into 1 ml aliquots. The vials were placed into the -80 °C freezer and kept 
as the original virus stock. One aliquot was further diluted (1:100) and divided into 
1 ml aliquots and frozen as the master virus stock. To create a working virus 
stock, four vials of the latter dilution were used to infect subconfluent CRFK- cells 
prepared in flasks at a low multiplicity of infection (see below). The remaining 
aliquots were frozen and stored at -80 °C as master virus stock.  
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3.2.6. Propagation and Storage of Virus 
Eight T-25 flasks containing subconfluent monolayers of CRFK-cells were 
inoculated with 0.5 ml (approx. MOI 0.004) of the virus suspension. The medium 
was discharged, the cells were washed with PBS, and the virus suspensions 
were added to each flask. During the inoculation period of 60 min, the flasks were 
placed on a rocking platform to facilitate a homogenous distribution. Then 5 ml of 
low serum medium (supplemented D-MEM, high glucose, 2 % FBS) was added 
to each flask and the flasks were placed into the incubator. For three consecutive 
days, the cell layers were evaluated microscopically for maximal cytopathic 
effects (see Figure 3.1(a), 3.1(b) and 3.1(c)). On the third day, the flasks were 
exposed to three freeze-thaw cycles, to break cell structures open and release 
virus particles. The contents of each flask were collected, pooled and centrifuged 
at 1200 × g for 10 minutes. The supernatant was collected and frozen in aliquots 
and stored at -80 °C. The working virus stock contained a total of 176 aliquots 
(0.5 ml/vial). 
 
3.2.7. Confirmation of Virus in Culture 
3.2.7.1. Cytopathic Effect 
Morphological alterations in the CRFK-cell culture were observed using an 
inverted light microscope (microscopic magnification x 100, x 400) only a few 
hours (5 - 6 hrs) after inoculation with FHV-1. Cells became spherical, showing 
cluster appearance and spindle formation in the unstained and unfixed cultures. 
At 36 hours post infection, cell cultures showed complete virally induced 
cytopathic effects (CPE +++). By then, most cells had become lysed, few 
multinucleated giant cells (syncytia) with granulated cytoplasma could be 
observed and cells had detached from the flask’s surface.  
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3.1(a) 
Figure 3.1(a). Confluent monolayer of uninfected CRFK-cells in culture 
(unstained; microscopic magnification x 400) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.1(b) 
Figure 3.1(b). Confluent monolayer of FHV-1 infected CRFK-cells 6 hours post 
inoculation in culture. Cells are more distinct and few spherical cells are seen 
(black arrows) (unstained; microscopic magnification x 400). 
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3.1(c) 
Figure 3.1(c). Cytopathic effects of FHV-1 in CRFK-cells 36 hours post virus 
inoculation. Cells have become spherical and have detached from the surface of 
the cell culture flask. Some cells have formed clumps (unstained; microscopic 
magnification x 400). 
 
 
3.2.7.2. Transmission Electron Microscopy  
A drop of virus containing supernatant (collected as described in 3.2.6.) was 
placed on a sheet of Parafilm. A formvar-carbon coated electrone microscopy 
grid was placed on top for 30 min. The grid was removed and excess liquid 
drained off. Then the grid was touched to a drop of 2 % phosphotungstic acid 
(PTA) and stained after excess liquid was drained off. The grid was examined 
with TEM and the virus group was identified by the prominent cubic icosahedral 
shape of the capsid, the capsomere virus structure and envelope. The examined 
virus suspension contained numerous negatively stained virus particles. Most of 
the virions appeared with intact envelopes but to a greater extend virions without 
envelope could also be observed. The envelopes were distended to various 
degrees and therefore, the dimensions of the virions varied between 100 - 200 
nm in diameter. Most of the nucleocapsids were distinct and intact showing the 
characteristic cubic icosahedral shape of a herpesvirion while some capsids were 
disrupted and stain-penetrated. The ultrastructural features of the virion seen by 
TEM at a microscopic magnification of x 10,000 confirmed the identity of the 
herpesvirus family. 
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50 nm 
Figure 3.2. The electron micrograph shows a negatively stained FHV-1 virion. 
Staining and dehydration have distorted the virion. Stain has penetrated the 
distended envelope (black arrow), The nucleocapsid (white arrow) is intact 
(microscopic magnification x 10,000). 
 
 
3.2.7.3. Fluorescent Antibody Staining 
A direct immunofluorescent antibody (IFA) staining was performed to identify 
FHV-1. Therefore, cells at a seeding density of 0.74 x 106 cells/ml (200 µl/well) 
were cultured in 96-well plates for 24 hours. Serial dilutions of virus stock from 
10-3 through 10-10 were prepared. The growth medium was discharged and the 
cells were washed twice with PBS (200 µl/well). PBS in rows 11 and 12 was 
replaced by maintenance medium (300 µl/well). In the remaining wells, PBS was 
replaced by the virus dilutions (inoculation pattern see Figure 3.4). During the 
inoculation period of one hour, the plates were kept on a rocking platform. 
Following the inoculation period, the plates were read on an inverted light 
microscope and dilutions with few CPEs were marked on the plate lid. The plates 
were washed three times with PBS to discharge virus that had not attached. 
Maintenance medium was added and the plates were incubated for 48 hrs. 
Following the incubation period, the suspensions were shaken out of the 
microtiter plates into a prepared waste vessel and allowed to drain over a sterile 
paper towel. Remaining media was rinsed out with PBS and the plates were 
again shaken out over the waste vessel. For the fixation of cells, 80 % acetone 
(200 µl/well) was added and the plates were put into the freezer (-80 °C) for 20 
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minutes. The plates were allowed to air dry and the acetone to evaporate. Each 
well was overlaid with 50 µl of Fluorescein Isothiocyanate (FITC)-labeled 
antibody (AmericanBioResearchLab, Sevierville, TN, USA, Cat. Nr. 210-41) and 
incubated at 37 °C for 30 minutes. Prior to reading the wells, the plates were 
rinsed another three times and shaken out, but residual PBS was allowed to 
remain in the plates. The microtiter plates were read on the IFA microscope and 
plaques were identified by the intensive green fluorescent staining of FHV-1 
(Figure 3.3).  
 
 
Figure 3.3. Fluorescent microscopic picture of a FITC-stained viral plaque in a 
CRFK-cell monolayer 4 hrs post FHV-1 inoculation. Viral plaques are distinct and 
easily identified due to the intensive green fluorescence of the adjoining infected 
cells (microscopic magnification x 100) 
 
 
 
3.2.7.4. Quantal Assay 
To evaluate the quantity of the working virus stock, a virus titration was 
performed in quadruplicate plates (n = 10 per dilution and plate; control n = 112) 
and repeated several times using five individual samples from the frozen working 
stock. Therefore CRFK-cells were incubated in 96-well plates for 48 hrs. The 
virus dilutions were prepared in low serum medium and the assay was performed 
in 10-fold dilutions from 10-1 to 10-12 (see Figure 3.4). Following the one hour 
inoculation period the plates were incubated for 48 hours. The plates were read 
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using an inverted light microscope (microscopic magnification of x 100 and          
x 400), CPEs were documented for each well.  
The tissue culture infectious dose 50 (TCID[50]) was determined for each 
individual assay using the Reed-Muench Method and an average titer of         
108.7 TCID[50]/ml was determined for the working virus stock (see 9.3 for Reed-
Muench Method).  
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Figure 3.4. Exemplary inoculation pattern for virus titration and IFA-staining. 
Subsequent dilutions are prepared on additional plates following the same 
inoculation pattern. 
  
 
3.3. Experimental Methods 
3.3.1. Infectivity Plaque Assay 
To standardize the virus suspension (PFU/ml) for the experiments plaque assays 
were performed in serial dilutions. CRFK-cells were seeded at a density of        
0.2 x 106 cells ml-1 per well into 24-well tissue culture treated plastic plates. After 
a 24 hr incubation period (at 37 °C and 5 % CO2/ 95 % O2), the cells had grown 
into a 90 % confluent monolayer in each well. The medium was replaced by an 
inoculum of each virus dilution at 0.1 ml/well. Over the inoculation period of one 
hour, the plates were placed on a rocking platform to secure a homogenous 
distribution of virus particles. After removing the virus suspension from the wells, 
the cells were washed three times with PBS and 1 ml overlay media (1.6 % 
Seaplaque Agarose 1:1 2X DMEM high glucose, supplemented and with 2 % 
FBS) was added to each well. Once the overlay media had solidified, the plates 
were incubated for 72 hrs. For the fixation of cells, 1 ml of a 10 % formalin 
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suspension was added to each well and left for 4 hrs at room temperature. The 
formalin was collected and the overlay plugs were gently washed out with 
deionized (DI) water. To stain the cells, several drops of 0.1 % (w/v) crystal violet 
were added to each well and rinsed out with DI water after 15 min. The plaques 
were then counted microscopically (microscopic magnification x 100 and x 400) 
and expressed as plaque forming units per milliliter (PFUs per ml). The virus 
challenge dose for subsequent plaque reduction experiments was estimated from 
the observed relationship between the tested virus dilutions and PFUs per ml as 
a function of the virus dilution. 
 
3.3.2. Antiviral Plaque Reduction Assay 
Several plaque assay protocols were tested and a protocol by LYLE J. BROWN 
(L.J. BROWN PERSONAL COMMUNICATION, SOUTH DAKOTA 2003) was most suitable 
for the experiment after modification (i.e. viral input, overlay media formulation, 
treatments) for the use with CRFK-cells and FHV-1. 
Confluent monolayers of CRFK-cells were grown in 24-well cell culture plates. 
Cells were treated either with rFeIFN-ω (Virbagen® Omega) or rHuIFN-α2b over 
a set of serial dilutions (100 U/ml, 250 U/ml, 500 U/ml, 1,000 U/ml, 2,500 U/ml, 
5,000 U/ml, 10,000 U/ml, 25,000 U/ml, 50,000 U/ml, 100,000 U/ml, 250,000 U/ml 
and 500,000 U/ml). The interferons were added at three different time points 
relative to virus exposure in order to maintain the dosages throughout the 
experiment. The cells were treated six hours before addition of virus, concurrent 
with addition of virus (30 PFU/ml-1/well), and together with the overlay medium 
(2X DMEM 1:1 with 1.6 % Agarose). Before each treatment, the cell cultures 
were washed three times with PBS. Treatments and virus controls were 
performed in duplicates. Control cell cultures were treated exactly as test cell 
cultures but received PBS instead of interferons. For each assay, an additional 
control plate was used to control for possible plate effects. Following incubation 
for 72 hrs, the cells were fixed with 10 % formalin, overlay plugs were discarded 
and the remaining cell layers were stained with crystal violet (described above). 
All plaques per well were counted twice under an inverted microscope 
(microscopic magnification x 400) and mean plaque counts were calculated from 
two wells per dilution and assay. Each assay was repeated on six occasions to 
confirm reproducibility.  
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Figure 3.5. Exemplary inoculation pattern used during the plaque reduction assay 
for IFN-treated test units and virus controls. Subsequent treatments are prepared 
on additional plates following the same inoculation pattern and plate division. 
 
 
3.3.3. Plaque Size Reduction 
For the evaluation of plaque area reduction, plaques in treated cell cultures (with 
100,000 U/ml, n = 20; 250,000 U/ml, n = 40 and 500,000 U/ml, n = 40) and 
controls (0 U/ml, n = 100) were examined. Plaques were randomly chosen and 
their diameters (d = 2 x r, with d = diameter and r = radius) were measured using 
a microscopic measuring reticule. Plaque areas were calculated with the formula 
a = r2  x  π (with a = plaque area, r = radius), assuming that a circle would best 
describe their shape. Plaque areas of interferon treated cell cultures compared to 
controls were analyzed.  
 
 
3.3.4. Cytotoxic Assay 
The MTT-assay is widely used to determine the toxicity of drugs on the cellular 
level. It measures the cell proliferation rate and conversely, when metabolic 
events lead to apoptosis or necrosis, the reduction in cell viability. It is possible to 
accurately quantify changes in the rate of cell proliferation because there is a 
linear relationship between the number of cells and the signal produced in the 
assay.  
The reduction of tetrazolium salt, MTT (3–(4, 5–dimethylthiazolyl–2)–2, 5–
diphenyltetrazolium bromide), results in the intracellular accumulation of purple 
formazan that can be dissolved in an organic solvent and quantified by 
spectrophotometry. Events that adversely affect cell viability are measured as a 
decrease in the reduction process of MTT to formazan.  
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Two assays with 16 replicates per dilution were performed in 96-well cell culture 
plates, which were seeded with CRFK-cells (density 0.75 x106 cells/ml, 200 µl per 
well). In each of the test wells growth medium was supplemented with either 
rFeIFN-ω or rHuIFN-α2b (10-fold dilutions ranging from 500 U/ml to 500,000 
U/ml). Reference metabolic activity control wells (“alive”) received growth medium 
without rFeIFN-ω and cell-death controls (“dead”) were treated with ethanol to 
obtain 100 % cell death. The plates were incubated at 37 °C for 12 hrs. The 
medium was aspirated and replaced with 100 µl of medium containing 0.5 mg/ml 
MTT solution. Following an incubation period of 5 hrs, 90 µl of the medium of 
each well was removed and replaced with 90 µl of solubilization solution           
(0.1 N HCL/Isopropanol). The plates were incubated for an additional 5 minutes. 
To dissolve the formazan crystals, the contents of each well were mixed using a 
multichannel-pipette. The plates were read at 570 nm and 630 nm. Optical 
densities (OD) at 630 nm were subtracted from OD at 570 nm and the average 
corrected ODs were calculated for each dilution and compared with the values of 
both control groups.  
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Figure 3.6. Exemplary plate division for MTT-Assay. IFN-treated test units and 
virus controls are included. 
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3.4. Statistical Procedures 
Regression analysis was used to evaluate the optimal dosage for the virus 
challenge dosage and trend analysis for plaque reduction and drug dosages. 
One-way Analysis of variance (ANOVA) was performed using JMP statistical 
software (JMP,Statistical Software, SAS Institute Inc. Cary, NC, USA).  
For drug induced plaque number and plaque size reduction and corrected optical 
densities obtained in MTT-assay means were compared using a Dunnett’s-test 
with a significance level of p ≤ 0.05. 
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4. Experimental Results 
4.1. Infectivity Plaque Assay 
The virus challenge dose for subsequent plaque reduction experiments was 
estimated from the observed relationship between the six virus dilutions tested 
and counts of the plaque forming units (PFUs) per milliliter as a function of the 
virus dilution. A regression analysis showed that the data was well described by a 
straight line (r2 = 0.98). PFU counts increased significantly with increasing virus 
concentration (decreasing virus dilution) (ANOVA: F1,130= 6332, p<0.0001) (see 
Figure 4.1(a)). Figure 4.1(b) shows the data and the regression line of Figure 
4.1(a) plotted with a logarithmic scale for the x-axis. Figure 4.1(b) shows more 
clearly the lower three dilutions which are compressed together in Figure 4.1(a); 
the regression line is transformed into a curve as a result of changing to a log 
scale. The virus dilution of 10-6.0 (approx. titer of 102,7TCID[50]/ml) produced an 
average of 320 PFU/ml. This virus concentration was chosen for the subsequent 
plaque reduction assay as it produced distinct plaques and plaque counts 
showed low variability (SEM +/-11.952).  
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Figure 4.1(a). Relationship between virus dilution (U/ml) and the amount of 
PFU/ml counted in CRFK-cells across the tested dilutions 72 hours post infection. 
The equation for the linear regression line is given. Dagger (†) indicates virus 
challenge dosage producing an average of 320 PFU/ml (approx. 102,7 
TCID[50]/ml). Since the virus dilutions were in approximate log steps, the data is 
compressed at lower virus concentrations 
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Figure 4.1(b). Same data as in Figure 4.1(a) plotted using a logarithmic scale for 
the horizontal axis.  
 
 
 
4.2. Antiviral Activity of rHuIFN-α and rFeIFN-ω  
4.2.1. Plaque Number Reduction 
Mean plaque counts for the 12 concentrations per drug and the control condition 
(untreated CRFK-cells) are shown in Figure 4.2. Dark shaded bars show the 
counts for rFeIFN-ω (± 1 SEM) and light shaded bars show the counts for 
rHuIFN-α2b. None of the treatments resulted in a complete suppression of 
plaques. The effect of the drugs on the plaque formation was assessed 
statistically for both drugs and each of the twelve dilutions using Dunnett’s 
procedure for testing multiple treatments against a control. This analysis showed 
that the plaque counts in drug-treated conditions were only significantly different 
from control counts for the higher concentrations of rFeIFN-ω. The treatments of 
100,000 U/ml resulted in a plaque count reduction of 54.7 % (p< 0.05) and at 
500,000 U/ml a plaque reduction of 59.8 % (p< 0.05); these concentrations are 
marked with asterisks in Figure 4.2. Figure 4.3(a) and Figure 4.3(b) show the 
mean plaque count reduction (%) relative to the control across all tested IFN 
treatments including results of the linear regression analysis. Asterisks indicate 
significant plaque reduction (p<0.05) compared to control group. None of the 
treatments with rHuIFN-α2b resulted in a statistically significant plaque count 
reduction. However, two of the tested concentrations (5,000 U/ml, p=0.078;      
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100 U/ml, p= 0.099 were found to be close to being statistically significant        
(p> 0.05 but less than 0.1) but did not reach the requirements to be statistically 
reliable.  
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Figure 4.2. Mean plaque counts for all tested IFN-dilution treatments and the 
untreated control (dark shaded). Dark bars are the mean counts for rFeIFN-ω; 
light bars represent the mean counts for rHuIFN-α2b. Concentrations are 
expressed as U/ml. Error bars show ± 1 SEM. Asterisks indicate statistically 
significant plaque reduction relative to the control condition (p< 0.05)  
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Figure 4.3(a). Mean plaque count reduction (%) relative to the control across all 
tested IFN-treatments (error bars show ± 1 SEM). Plaque count reduction for the 
rFeIFN-ω treatments, shown with the results of the linear regression analysis. 
Asterisks indicate significant plaque reduction (p<0.05) compared to control 
group 
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Figure 4.3(b). Mean plaque count reduction (%) relative to the control across all 
tested rHuIFN-α2b concentrations (Log10/ml), together with the results of the 
linear regression analysis. 
 
 
 
4.2.2. Plaque Size Reduction 
Mean plaque areas at each of the drug concentrations were expressed as a 
percentage of the mean area obtained in the untreated control condition 
(infected, untreated CRFK-cells). Plaque area reduction for rFeIFN-ω and 
rHuIFN-α2b at the tested concentrations is shown in Figure 4.4. Plaque area 
reductions of over 50% were observed in infected CRFK-cell cultures treated with 
rHuIFN-α2b and for those treated with rFeIFN-ω. Plaque areas at all tested 
concentrations of rFeIFN-ω and rHuIFN-α2b were found to be significantly 
reduced relative to the untreated controls (p<0.05). The mean percent area 
reduction for rFeIFN-ω for 100,000 U/ml was 47.5% for 250,000 U/ml 81% and 
for 500,000 U/ml 70.5%. The mean percent area reduction for rHuIFN-α2b for 
100,000 U/ml was 56.4 %, for 250,000U/ml 75.7 % and for 500,000 U/ml 69.8 % 
(as shown in Figure 4.4).  
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Figure 4.4. Mean percentage of plaque area reduction following either rFeIFN-ω 
and rHuIFN-α2b treatment with plaque area expressed as percent of the mean 
control plaque area. Asterisks indicate statistically significant plaque area 
reduction (p<0.0001) compared to infected, untreated cells. 
 
 
 
4.2.3. Micrographs 
Micrographs were taken in order to document plaque areas of all tested 
concentrations. Figure 4.5(a) shows the FHV-1 infected untreated CRFK-cell 
culture with a white-dotted line circumscribing the extension of an average plaque 
in the control condition. Figure 4.5(b) and 4.5(c) show an average plaque in FHV-
1 infected, rHuIFN-α2b (b) and rFeIFN-ω (c) treated CRFK-cell cultures. A white-
dotted line circumscribes the plaque areas for better illustration.  
 
 
 
 
 
 
 
 
 48
4. EXPERIMENTAL RESULTS 
 
Figure 4.5(a). Micrograph of plaque in infected, untreated CRFK-cell culture. 
Uninhibited cell-to-cell spread results in significantly larger plaques compared to 
treated cultures (crystal violet; microscopic magnification x 400)  
 
 
Figure 4.5(b). Micrograph of plaque in infected, rHuIFN-α2b-treated (500,000 
U/ml) CRFK-cells in culture. Plaques are significantly smaller compared to control 
(crystal violet; microscopic magnification x 400) 
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Figure 4.5(c). Micrograph of plaque in infected, rFeIFN-ω-treated (500,000 U/ml) 
CRFK-cell culture. Plaques are significantly smaller than in untreated cells. 
(crystal violet; microscopic magnification x 400). 
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4.3. Cytotoxic MTT-Assay 
Neither rFeIFN-ω nor rHuIFN-α2b treatment caused significant cellular toxicity at 
the tested concentrations (500U/ml; 5,000U/ml; 50,000U/ml; 500,000U/ml). 
Optical density of rFeIFN-ω or rHuIFN-α2b treated cells were not significantly 
different from the cells in the medium alone (“Alive”-control) but were significantly 
different from death control cells (p<0.05, Figure 4.6.).  
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Figure 4.6. MTT-Assay for rHuIFN-α2b and rFeIFN-ω. Optical densities of tested 
IFN concentrations are compared towards controls (“alive” and “dead” cells). 
Asterisks indicate values, which are significantly different from “dead” control 
(p<0.05) but also significantly in accordance with “alive” control (p<0.05). 
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5. Discussion 
In the present study, the effect of rFeIFN-ω and rHuIFN-α2b on FHV-1 replication 
was tested in vitro. Plaque formation of other origin (i.e. toxic effects, 
contamination with other cytolytic viruses) was excluded and FHV-1-involvement 
confirmed by IFA staining. Both interferons were shown to have antiviral effects 
and both are therefore useful for the treatment of FHV-1 infected cats. As 
hypothesized, treatment with rFeIFN-ω was more effective than treatment with 
the heterologous rHuIFN-α2b. The results showed for the first time that treatment 
efficacy for interferon cannot only be measured in terms of a reduction of the 
number of viral plaques but also in terms of a reduction of their size. Cytotoxic 
effects that potentially could have contributed to the anti-viral effect of the drugs 
were excluded by MTT-assay.  
 
 
5.1. Experimental Results 
The results demonstrated that both rFeIFN-ω and rHuIFN-α2b have antiviral 
effects on FHV-1 in vitro. The extent to which either rFeIFN-ω or rHuIFN-α2b 
were able to confer significant protection against FHV-1 was assessed by the    
(a) number of plaques and (b) the sizes of plaques in treated cultures compared 
to untreated controls.  
There was some indication that the treatment with both rFeIFN-ω and         
rHuIFN-α2b resulted in a reduction of plaque number (Figure 4.2). However, the 
effect was found to be statistically significant only at the higher concentrations of 
rFeIFN-ω. A linear regression analysis showed that the size of the reduction 
increased with increasing concentration of rFeIFN-ω demonstrating that    
rFeIFN-ω has a dose dependent effect (Figure 4.3). None of the rHuIFN-α2b 
treatments resulted in a statistically significant plaque number reduction and 
there was no statistically detectable trend for the plaque reduction to be greater 
at higher concentrations (Figures 4.2 and 4.3).  
It cannot be concluded from these results that there is no antiviral effect of 
rHuIFN-α2b on FHV-1 replication. It can only be concluded that if there is an 
antiviral effect the assay technique is not sufficiently sensitive to detect it. That 
there is likely to be a small antiviral effect is suggested by the finding that two of 
the tested concentrations were found to be close to statistically significant          
(p > 0.05 but less than 0.1). As described below, using plaque size reduction 
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rather than plaque number reduction as a measure of antiviral activity did provide 
evidence for an antiviral effect of rHuIFN-α2b.  
The antiviral effect of rFeIFN-ω on plaque number was large enough to be 
detected by the assay technique, at least at higher concentrations (Figure 4.2). In 
agreement with reports by other authors, the in vitro antiviral activity of rFeIFN-ω 
was found to be dose-dependent (MOCHIZUKI ET AL., 1994). The most profound 
plaque reduction, obtained at the highest rFeIFN-ω concentration tested, was 
considerably less than that reported in previous studies (MOCHIZUKI ET AL., 1994; 
TRUYEN ET AL., 2001). However, there are major differences between the type of 
assays (e.g. treatments, viral input, cell line, anti-cellular effects) that influence 
the antiviral effect and contribute to the variation between those studies.  
In general, the susceptibility of cell cultures to interferon has been found to vary 
considerably depending on cell-line and interferon type (WECK ET AL., 1981; 
FUERST ET AL., 1986). Biological effects such as initiation by activation of 
receptors and different binding-affinity may influence the mechanism of antiviral 
efficacy. In addition, the number of cellular receptors for IFN can vary 
considerably from cell-type to cell-type (10 - 2000/cell) (FLINT ET AL., 2000). 
TRUYEN and co-investigators (2001) reported that the treatment with rFeIFN-ω 
resulted in a less profound effect in CRFK-cells than observed in equally treated 
fcwf-cells: the fcwf-cell line used was found to be 10-times more sensitive to the 
rFeIFN-ω treatments than the CRFK-cells (TRUYEN ET AL., 2001). This may be 
attributable to a lower number of the IFN-receptor expression by CRFK-cells 
(TRUYEN ET AL., 2001).  
Both MOCHIZUKI ET AL. (1994) and TRUYEN ET AL. (2001) used virus yield reduction 
assays for testing the effect of interferon on FHV-1 replication. Thus, the virus-
yield reduction assay differs procedurally from the PR assay used in the current 
study: the former has a higher viral input, lacks an overlay media, involves 
freezing of the virus suspension and the assay procedure is of much longer 
duration. As is true for all biological assays, the exact concentration of an antiviral 
required to inhibit the replication of a virus depends on the infectivity input of the 
virus (MOI), the cell type used, the duration of the experiment, the kinetic of 
infection in that particular cell type and the sensitivity of the assay being used 
(SWIERKOSZ AND BIRON, 1995). It is to be expected that the yield reduction assay 
will result in more profound reduction due to the higher viral input. It is currently 
unknown whether clinical results are better correlated with the results obtained 
from the yield reduction assay or with the PR assay used here. This is a matter 
for further study. Thus, further empirical research is needed to determine why 
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differences existed between the antiviral effects of rFeIFN-ω reported here and 
those reported earlier.  
The results using the plaque size measurements demonstrated statistically 
reliable plaque reduction relative to untreated controls with both rFeIFN-ω and 
rHuIFN-α2b at the higher concentrations examined (Figure 4.4). The plaque size 
reductions observed were similar for both rFeIFN-ω and rHuIFN-α2b (Figure 4.4).  
This demonstrates that rHuIFN-α2b did have an antiviral effect in the cell cultures 
used in the study reported, but this effect could only be reliably detected using 
the plaque size measure.  
The host specificity of type I interferons is well known and maximal antiviral 
activity is described in homolog cells (FULTON AND BURGE, 1985; WEISS, 1989; 
WEISS ET AL. 1991). In contrast, previous observations of anti-FHV-1 activity in 
fcwf-cells or in feline lung cells have shown rHuIFN-α subtypes to inhibit FHV-1 
replication in vitro (FULTON AND BURGE, 1985; WEISS, 1989).  
None of the high-dose treatments of either rHuIFN-α2b or rFeIFN-ω caused 
significant cellular toxicity. Therefore, the anti-viral activity demonstrated by both 
interferons is not attributable to an in vitro effect on the cellular viability of CRFK-
cells. As mentioned before (section 2.5) it has been suggested that CRFK-cells 
are less susceptible to IFNs in vitro. This may also explain that there was no 
cytotoxic effect measured in the MTT-Assay. However, the absence of 
cytotoxicity in in vitro tests does not necessarily exclude toxicity in vivo.   
The results can be summarized as follows: rFeIFN-ω had a dose dependent 
antiviral effect that could be reliably detected at higher concentrations                 
(> 50,000 U/ml) using both the plaque number and plaque size measurements. 
rHuIFN-α2b also had an antiviral effect but this could only be detected at high 
concentrations using the plaque size measure; there was no statistical evidence 
for a reduction in plaque number. As described earlier, the two measures of anti-
viral activity (plaque number and plaque size) are likely to capture different 
aspects of the activity of the anti-viral agent. One action of IFNs is to inhibit viral 
replication within an infected cell. This action of the drug is expected to primarily 
affect plaque number. A second action of IFN is to protect an uninfected cell from 
infection by a virus. This action will affect the extent to which viral infection can 
spread from an infected cell to its neighbors and so is expected to primarily affect 
plaque sizes. This would mean that a somewhat similar effect of rHuIFN-α2b and 
rFeIFN-ω on plaque size reduction indicates a similar ability to protect uninfected 
cells against viral infection. The greater plaque number reduction observed with 
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rFeIFN-ω would indicate that this IFN has a greater ability to inhibit viral 
replication in infected cells. 
There is currently no direct evidence that rHuIFN-α2b and rFeIFN-ω differ in the 
mechanism of their antiviral action and so the observed differences in their 
efficacy cannot, at this stage, be directly attributed to a difference in mechanism. 
However, since the two proteins differ in their molecular structure they may differ 
in binding affinity or cellular receptor specificity. This may result in a later 
stimulation of the induction of the antiviral state in culture. However, at this time 
too little is known to be able to say anything definitive concerning the differences 
observed in the current study. 
 
5.2. Clinical Implications 
The predictive value for clinical application based on in vitro studies is limited due 
to the different conditions in vivo and individual metabolic conditions of animal-
patients. Nevertheless, the results of the present in vitro study suggest that either 
rFeIFN-ω or rHuIFN-α2b may be of prophylactic and therapeutic clinical value if 
given at high-doses early during FHV-1-infection. Use of rFeIFN-ω is likely to be 
the more effective. 
The ability of the test-compounds to inhibit viral cell-to-cell spread may be 
relevant for clinical applications such as the topical treatment of FHV-1 induced 
dendritic keratitis. It is likely that inhibition of viral spread will act to restrict the 
development of dendritic ulcers. This possibility needs to be tested directly, not 
only because the study reported here was in vitro but also because the cell 
culture used was different to that of the intended clinical application (cornea 
cells). 
A recent clinical study reported most profound clinical improvement of ocular 
FHV-1 manifestations following the topically treatment with rFeIFN-ω (VERNEUILE, 
2004). The effects of the feline interferon were evaluated over a wide range of 
concentrations and it was interesting that the most profound improvement was 
observed at the same high-dose treatment (500,000 U/ml) that proved effective in 
the present study. Furthermore, high-dose treatment with the same concentration 
resulted in a prolonged biological activity of rFeIFN-ω, measured by the 
expression of Mx-proteins in cats (BRAECKLEIN ET AL., 2003). In both studies a 
dose-dependent response was observed (BRAECKLEIN ET AL., 2003; VERNEUIL, 
2004). This indicates that the results from the test-systems used in the present 
study may apply to corneal cells in vivo.  
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Both interferons tested have immune modulating properties including the 
increase of the expression of class I MHC molecules and induce cellular anti-viral 
responses i.e. cytolytic activity of NK cells which inevitably result in a limited 
spread of progeny virus but also in loss of infected tissue. (FLINT ET AL., 2000; 
BIRON, 2001; ABBAS AND LICHTMAN, 2003). IFNs Thus, an enhanced effect of 
antiviral activity of these interferons may be expected in vivo. 
In the question of value for the heterologous rHuIFN-α2b compound, there is the 
question how long the compound will be of clinical value as the continued efficacy 
of heterologous IFNs has been demonstrated to induce the formation of cytokine-
specific neutralizing antibodies. Cats infected with established feline leukemia 
virus (FeLV)-acquired immunodeficiency syndrome (FAIDS), resistance to the 
HuIFN treatment due to neutralizing antibodies has been described previously 
(ZEIDNER ET AL., 1990).  
 
 
5.3. Conclusions 
This study was able to demonstrate anti-FHV-1 activity using high concentrations 
of rFeIFN-ω or rHuIFN-α2b in vitro. In addition, rFeIFN-ω was found to be more 
effective than rHuIFN-α2b, particularly in its ability to reduce plaque number. 
High-dose treatment with rFeIFN-ω or rHuIFN-α2b resulted in significant plaque 
size reduction indicating potential efficacy on reducing the dimensions of FHV-1 
induced cytopathic lesions. This might be relevant for clinical application and it 
would be worthwhile to test for an effect for the treatment of FHV-1 infection in 
cornea cells. 
Treatment with rFeIFN-ω has shown more profound effects in antiviral activity 
compared to rHuIFN-α2b and, in contrast to rHuIFN-α2b, it also offers the 
advantage of a homologous compound. This is consistent with the results 
obtained on in vivo activity, which have shown that high-dose IFN treatment 
shows good antiviral efficacy and clinical improvement. Therefore, there are 
indications that rFeIFN-ω may provide effective prophylactic and therapeutic 
treatment for FHV-1 infected cats.  
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6. Zusammenfassung 
Das feline Herpesvirus-1 (FHV-1) ist ein weltweit bei Katzen vorkommendes 
DNA-Alphaherpesvirus, das neben den Oberflächenepithelien des 
Respirationstrakts auch die Konjunktiven infiziert. Der Erreger stellt eine der 
wichtigsten Ursachen des Katzenschnupfens dar und wird als häufigste Ätiologie 
bei der Konjunktivitis und auch der Keratits der Katze nachgewiesen. Vor allem 
bei Tieren, die in Gruppen gehaltenen werden, ist eine hohe Inzidenz (> 70 %) 
feststellbar. Im Anschluss an eine Primärinfektion entwickeln fast alle Katzen     
(> 80 %) einen Trägerstatus. In der Latenzphase persistiert das Virus 
hauptsächlich im Trigeminalganglion, aus dem es spontan oder durch eine Reihe 
anderer Ursachen (u.a. Stress, Cortisontherapie) zu einer Reaktivierung der 
Erkrankung und Virusausscheidung kommen kann. Eine Therapie der FHV-1 
Infektion mit Virostatika (z.B. Aciclovir) ist sowohl systemisch als auch lokal 
möglich, aber umstritten, da sie in einigen Fällen nur geringe Wirkung zeigt, und 
die systemische Anwendung mit erheblichen toxischen Nebenwirkungen 
verbunden ist. Die erfolgreiche Behandlung, vor allem der bei persistierenden 
Infektionen wiederkehrenden okulären Manifestationen, stellt eine therapeutische 
Herausforderung dar.  
In der Literatur wird die Anwendung humaner und feliner Interferone und ihre 
antivirale Wirkung gegen ausgewählte feline und canine Viren beschrieben 
(JAMESON & ESSEX, 1983; FULTON & BURGE, 1985; WEISS & TOIVIO-KINNUCAN, 
1988; WEISS, 1989; WEISS & OOSTROM-RAM, 1990; TRUYEN ET AL., 2001). Bisher 
existieren aber nur zwei in vitro Studien, die auf eine vielversprechende Wirkung 
des rFeIFN-ω in der Behandlung der FHV-1 Infektion hinweisen (MOCHIZUKI ET 
AL., 1994; TRUYEN ET AL., 2001).  
Es war Ziel dieser Studie, den antiviralen Effekt des humanen rHuIFN-α2b 
(Intron®-A) sowie des felinen rFeIFN-ω (Virbagen®-ω) auf die Replikation von 
FHV-1 in vitro zu untersuchen und miteinander zu vergleichen. Dabei sollte im 
Gegensatz zu bisherigen Untersuchungen (WEISS, 1989; MOCHIZUKI ET AL., 1994, 
TRUYEN ET AL., 2001) die Wirkung eines breiteren Spektrums (100 U/ml – 
500,000 U/ml) von Interferon-Konzentrationen untersucht werden. Dieses 
Spektrum wurde gewählt, um beschriebene Konzentrationen zu wiederholen und 
um zu untersuchen, ob eine dosisabhängige Wirkung sowie eine eventuell 
optimale Dosis der Interferone vorlägen.  Aufgrund der engen Spezies-Spezifität 
wurde bei der Behandlung mit dem homologen rFeIFN-ω im Vergleich zu dem 
heterologen rHuIFN-α2b ein deutlicherer Effekt erwartet. Der 
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Plaquereduktionstest sowie alle Zell- und Viruskultur-Techniken mussten dazu 
vor Beginn der Experimente etabliert werden. Ausserdem konnte erstmals 
gezeigt werden, dass die antivirale Wirksamkeit von Interferon auch anhand der 
Plaquegrösse quantifiziert werden kann. Um einen Zusammenhang zwischen 
einem antiviralen Effekt und einer zelltoxischen Wirkung beider Interferone 
auszuschliessen, wurde die Zellstoffwechselaktivität behandelter im Vergleich zu 
unbehandelter Zellkulturen in MTT-Assays untersucht.  
Im Plaquereduktionstest wurde die Wirkung von jeweils 12 abgestuften 
Konzentrationen (100 U/ml bis 500.000 U/ml) pro Interferon (rFeIFN-ω, rHuIFN-
α2b) in Duplikaten untersucht und sechsmal wiederholt. Dazu wurden CRFK-
Zellen in 24-Zellkultur-Lochplatten ausgesät und über Nacht inkubiert. Die 
Zugabe der jeweiligen Interferonlösungen erfolgte sechs Stunden vor 
Virusinkubation und wurde über den weiteren Verlauf des Versuchs 
aufrechterhalten. Als Kontrolle dienten CRFK-Zellen, die jeweils an Stelle von 
Interferon phosphat-gepufferte Kochsalzlösung (PBS) erhielten, abgesehen 
davon aber den gleichen experimentellen Bedingungen ausgesetzt waren wie die 
Versuchsgruppen. Im Anschluss an die 72 stündige Inkubation wurden die Zellen 
fixiert, das Overlay-Medium wurde entfernt und die Zellrasen mit Kristallviolett 
gefärbt. Die Anzahl der Plaques (pro Vertiefung und Interferonkonzentration) 
konnte unter dem invertierten Lichtmikroskop gezählt und anschliessend 
ausgewertet werden. Die Erfassung einzelner Plaquesdurchmesser erfolgte 
mikroskopisch mit einem Meβokular.  
Das MTT-Assay wurde in 96-Mikrotiterplatten mit CRFK–Zellen durchgeführt. Die 
Wirkung der Interferone wurde für jede Konzentration in acht Parallelansätzen 
(n=16)  ermittelt und zweimal durchgeführt. Als Referenz dienten eine Lebend-
kontrollgruppe, in der die Interferonbehandlung durch PBS ersetzt wurde und 
eine Totkontrollgruppe, in der die Zellen mit Ethanol abgetötet worden waren. Die 
Mikrotiterplatten wurden inkubiert und anschliessend wurde das Medium durch 
MTT-haltiges Medium ersetzt. Nach weiterer Inkubation wurde das Medium durch 
einer HCL/Isopronalol-Lösung ersetzt, um die Kristalle aufzulösen. Die optischen 
Dichten in den Vertiefungen wurden spektrophotometrisch gemessen. 
Anschliessend wurden die mittleren optischen Dichten errechnet und mit den 
Kontrollwerten verglichen.  
Zur statistischen Auswertung der Experimente wurde eine ANOVA und der 
Dunnett-Test herangezogen. Eine signifikante Plaquezahlreduktion konnte nur in 
den mit rFeIFN-ω behandelten Zellkulturen festgestellt werden. In den 
Konzentrationen 100.000 U/ml und 500.000 U/ml ergab die Anzahl der Plaques 
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eine Reduktion um 54,7 % (p<0,05) bzw. um 59,8 % (p<0,05) gegenüber den 
unbehandelten Kontrollen. Ausserdem konnte eine statistisch signifikante 
Reduktion der Plaquegröβe bei 100.000 U/ml von 47,5 %, bei 250.000 U/ml von 
81 % und bei 500.000 U/ml von 70,5 % gegenüber den unbehandelten Kontrollen 
festgestellt werden. rHuIFN-α2b induzierte in keiner der untersuchten 
Konzentrationen eine signifikante Plaquezahlreduktion. Dagegen konnte jedoch 
eine signifikante Reduktion der Plaquegröβe bei den Behandlungen mit 100.000 
U/ml, 250.000 U/ml, und 500.000 U/ml um 56,4 %, bzw. um 75,7 %, und um 69,8 
% nachgewiesen werden.  
Die optischen Dichten für rFeIFN-ω und rHuIFN-α2b waren für alle gemessenen 
Konzentrationen signifikant (p<0,05) übereinstimmend mit den optischen Dichten 
der Lebendkontrollgruppen und signifikant höher (p<0,05) verglichen mit den 
Werten der Totkontrollgruppe. Damit ist gezeigt worden, dass sowohl rFeIFN-ω 
als auch rFeIFN-α2b keine signifikante zelltoxische Auswirkung auf den 
Zellstoffwechsel hatte.  
Mit dieser Arbeit ist es im wesentlichen gelungen, die antivirale Wirkung  von 
rFeIFN sowie von rHuIFN-α2b auf die Replikation von FHV-1 zu bestätigen. Eine 
Dosis-Wirkungsbeziehung des rFeIFN-ω, sowie statistisch signifikanter 
Reduktion der Plaquezahl und Plaquegröβe konnte bei Behandlung mit hohen 
Konzentrationen (> 50.000 U/ml) von Interferon beobachtet werden. Mit der 
rHuIFN-α2b-Behandlung konnte keine statistisch signifikante 
Plaquezahlreduktion, aber eine signifikante Reduktion der Plaquegröβe nach 
Applikation hoher Konzentrationen (> 50.000 U/ml) festgestellt werden.  
Erst  kürzlich wurde in zwei in vivo Studien von einer guten antiviralen Wirkung 
hoher rFeIFN-ω Konzentrationen berichtet, welche die Ergebnisse der 
vorliegenden Studie bestätigen (BRAECKLEIN ET AL., 2003; VERNEUIL, 2004). 
Somit liegt die Vermutung nahe, dass besonders mit dem rFeIFN-ω ein Präparat 
zur Verfügung steht, das bei prophylaktischer und kontinuierlicher Applikation im 
Verlauf einer Infektion in der Lage ist, die Ausbreitung von Nachkommenviren 
und damit die Ausdehnung der zytotoxischen Läsionen in infiziertem Gewebe in 
vitro einzuschränken. 
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7. Summary 
Nicola Siebeck 
Efficacy of rHuIFN-α2b and rFeIFN-ω on Feline Herpesvirus-1 Replication in 
vitro 
Feline herpesvirus-1 (FHV-1)-infection, also known as feline viral rhinotracheitis 
(FVR) is distributed world wide in the cat population, with a high incidence in 
colony cats (>70%). FHV-1 typically infects and replicates in epithelial tissue of 
the upper respiratory tract and conjunctiva causing cytopathic lesions. The virus 
is recognized as one of the most important pathogens of feline upper respiratory 
tract infections, conjunctivitis and keratitis in cats. Following primary infection 
over 80% of cats are unable to eliminate the virus and develop a carrier state, 
with intermittent episodes of virus shedding. During latency, the virus persists 
most often in the trigeminal ganglion and the disease can be reactivated following 
stress and corticosteroid therapy.  
Successful treatment, particularly of ocular manifestations associated with 
recrudescent infection such as dendritic ulcers remains difficult. Available antiviral 
drugs are virostatic and in particular, the systemic application is associated with 
severe toxic side effects. Human natural and recombinant interferons and feline 
interferons have been described in their use against a selection of feline and 
canine viruses (JAMESON and ESSEX, 1983; FULTON and BURGE, 1985; WEISS 
and TOIVIO-KINNUCAN, 1988; WEISS, 1989; WEISS and OOSTROM-RAM, 1990; 
TRUYEN et al., 2001). To date, only two in vitro studies indicate a potent antiviral 
activity of the recombinant FeIFN-ω against FHV-1 (MOCHIZUKI et al., 1994, 
TRUYEN et al., 2001).  
The purpose of this study was to evaluate the antiviral efficacy of the recently 
available rFeIFN-ω (Virbagen®-ω) and the human rHuIFN-α2b (Intron®-A) on the 
replication of FHV-1 in vitro. A wider range of concentrations (100 U/ml – 500,000 
U/ml) was studied than used in the previous studies (WEISS , 1989; MOCHIZUKI et 
al., 1994, TRUYEN et al., 2001) in order to repeat previously tested concentration 
and further, to determine whether the drugs have a dose-dependant response of 
antiviral activity and which concentration would be the most effective treatment. 
The species-specificity of type I interferons is well known and therefore, it was 
suggested that rFeIFN-ω would result in a more profound effect compared to the 
rHuIFN-α2b due to its homologous nature. In addition to cell and virus culture 
techniques, a methodology for the plaque reduction assay was established. 
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Furthermore, for the first time antiviral efficacy for interferon was additionally 
measured by plaque size reductions and is reported in this study.  
An in vitro MTT-Assay was integrated in the experiment to exclude possible 
cytotoxic effects that could, in principle, contribute to the antiviral effects 
observed with either of the interferon treatments.  
For the plaque reduction assay, confluent monolayers of Crandell feline kidney 
(CRFK)-cells were grown in 24-well cell culture plates. Cells were treated with 
either rFeIFN-ω (Virbagen® Omega) or rHuIFN-α2b (Intron®-A) across a set of 
serial dilutions (100 U/ml - 500,000 U/ml). Cells were treated six hours before 
addition of FHV-1, concurrent with addition of FHV-1 and each drug 
concentration was added to the overlay medium (2X DMEM 1:1 with 1.6% 
Agarose). The treatments were performed in duplicates including virus controls, 
which received PBS instead of either one of the interferons and assays were 
performed on six occasions. Following incubation of 72 hrs, the cells were fixed 
with formalin, overlay plugs were discarded and the remaining cell layers were 
stained with crystal violet. Plaque numbers were counted under an inverted 
microscope and Plaque diameters were measured using a reticule.  
For the MTT-assay, 96-well culture plates were seeded with CRFK-cells. In each 
of the test wells (n=16) growth medium was supplemented with either       
rHuIFN-α2b or with rFeIFN-ω. Control wells (n=72) received growth medium with 
PBS instead of either one of the Interferons. Cell-death controls were treated with 
ethanol to obtain 100% cell death. After incubation, the medium was aspirated 
and replaced with medium containing the MTT-solution. Following another 
incubation period, the medium of each well was removed and replaced with a 
solubilization solution (0.1N HCL/Isopropanol). The plates were incubated for an 
additional five minutes to dissolve the crystals and the plates were read using a 
plate reader. The average optical densities were calculated for each dilution and 
compared with that of the positive control wells. A one-way ANOVA and 
Dunnett’s test were used for the statistical analysis of all experiments. 
A significant reduction of plaque numbers was observed for rFeIFN-ω at 100,000 
U/ml with a plaque reduction of 54.7 % and at 500,000 U/ml with a plaque 
reduction of 59.8 %. Plaque sizes were significantly reduced by 47.5 % at 
100,000 U/ml and by 81 % at 250,000 U/ml and 70.5% at 500,000 U/ml. 
Recombinant HuIFN-α2b treatment did not succeed to produce any significant 
plaque number reduction. However, significant plaque size reductions were 
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observed following treatment with 100,000 U/ml, 250,000 U/ml and 500,000 U/ml 
with reductions of 56 %, 75.7% and 69% respectively.  
None of the high-dose treatments of either rHuIFN-α2b or rFeIFN-ω caused 
significant cellular toxicity in the MTT-Assay. Therefore, the antiviral activity 
demonstrated by both interferons is not attributable to an in vitro effect on the 
cellular viability of CRFK-cells.  
In agreement with previous authors, this study was able to demonstrated that 
rFeIFN-ω and rHuIFN-α2b have inhibitory effects on the replication of FHV-1. For 
rFeIFN-ω the antiviral effect is dose-dependent and could be reliably detected at 
high concentrations (> 50,000 U/ml) using both the plaque number and plaque 
size measurements. Treatment with high concentrations of rHuIFN-α2b also 
resulted in an antiviral effect, which was only detected at using the plaque size 
measure; there was no statistical evidence for a reduction in the plaque number 
measurement. The significantly smaller plaque sizes in drug–treated cell cultures 
indicate that high-dose treatment with rFeIFN-ω or rHuIFN-α2b may have 
potential efficacy on reducing the dimensions of FHV-1 induced cytopathic 
lesions.  
Treatment with rFeIFN-ω has shown more profound effects in antiviral activity 
compared to rHuIFN-α2b and, in contrast to rHuIFN-α2b, it also offers the 
advantage of a homologous compound. This is consistent with recently published 
results obtained on in vivo activity, which have demonstrated that high-dose 
treatment of rFeIFN-ω shows good antiviral efficacy and clinical improvement 
(VERNEUIL, 2004; BRAECKLEIN et al., 2003). Therefore, there are indications that 
rFeIFN-ω may provide effective prophylactic and therapeutic treatment for FHV-1 
infected cats.  
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9. APPENDIX 
9. Appendix 
 
9.1. Media and Sera 
 
? Dulbecco’s Modified Eagle Medium (D-MEM), ( 1 x) 
high glucose, 1 x liquid with L-glutamine, with pyridoxine hydrochloride, 
without sodium pyruvate, Gibco Cat. # 11965-118 
 
? Dulbecco’s Modified Eagle Medium (D-MEM), (10 x) 
high glucose, 10 x powder without sodium bicarbonate and sodium pyruvate 
Gibco Cat. # 12100-046(1x) 
 
? Fetal Bovine Serum (FBS) 
qualified Origin: United States Performance, Mycoplasma, virus and 
endotoxin tested, 500 ml, Lot Nr. 1180094, Gibco Cat. # 26140 
Sera were heat inactivated at 56°C for 30 min  
 
9.2. Supplements and Reagents 
 
? Sodium Bicarbonate, powder, cell culture tested, 500 g,  
Lot # 062K0176, Sigma Cat. # S5761 
 
? L-glutamine, powder, cell culture tested, 25 g, 
Sigma Cat. # G-5763 
 
? Penicillin G and Streptomycin, frozen, containing 
Sodium penicillin G 10,000 U/ml and Streptomycin sulfate 10 mg/ml  
Sigma Cat. # P0781 
 
? Amphotericin B (Fungizone), 2,5µg/ml,  
powder, prepared with sterile water; Sigma Cat. # A9528  
 
? Dimethylsulphoxide (DMSO), 5 x 5 ml Ampules, 
Sigma Cat. # D2650 
 
? Dulbecco’s Phosphate Buffered Saline, liquid, 500 ml, 
Sigma Cat. # W3500 
 
? Trypsin-EDTA Solution, frozen, 0.25%, 0.53 mM EDTA 
Sigma Cat. # T4049, working solution: samples of 15 ml 
 
? Trypan Blue Solution 
VWR Cat. # 11173, working solution: 0.03 % (w/v) 
 
? Crystal violet 
Powder, solubilize with DI water 
CAS # 548-62-9, working solution: 0.01 % (w/v) 
 
? MTT Formazan, powder 
1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan, 57360-69-7,  
Sigma Cat. # M0032 
 
? Sea Plaque Agarose 100 G 
American Bioanalytic Sea Plaque Agarose 100G 
Cat. # NC9664839 through Fisher Scientific, working solution/ gel: 1,6% (w/v)  
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9.3. Titration of Virus Suspensions  
 
Example:  Reed and Muench Method 
 
Log of 
Virus 
dilution 
Infected 
test 
units 
Cumulative 
infected (A) 
 
Cumulativ 
non-infected 
(B) 
Ratio of  
A/ (A+B) 
Percent 
infected
 
-1 
 
10/10 
 
10+8+3 =21 
 
0 
 
21/21 
 
100% 
-2 8/10 8+3 =11 2+0= 2 11/13 85 % 
-3 3/10 3+0 =3 7+2 =9 3/12 25 % 
-4 0/10 0 7+2+10 =19 0/19 0 % 
Dilution that corresponds to 50 % lies somewhere between dilution 
10-2 and dilution 10-3
The proportionate distance between these two dilutions is 
calculated as follows: 
 
              (% positive above 50%)-50%_________  = Proportionate distance 
(%positive above 50%)-(%positive below 50%) 
 
85%-50% 8
            85%-25%
 
The 50 % end point is ca
As serial 10 fold dilution
(log dilution above 5
dilution factor) = log ID
 
i.e   (-2) + (0,58 x –1.0) =
 
Therefore ID50 = 10-1,42 
 
This is the endpoint dil
the test units inoculated
the virus titer in terms o
inoculation of virus di
suspension would theref
 
10 1,42 TCID50 x 0.1ml-1 
= 10 x 10 1,42 TCID ml–1
= 10 2,42 TCID50 ml-1 
  = 0,5 
lculated as follows: 
s where used, the log dilution factor is 1.0 
0%) + (proportionate distance x log 
50 
 1,42 
ution, i.e.the diltion that will infect 50% of 
.The reciprocal of this number gives rise to 
f infectious doses per unit volume. If the 
lution was 0.1ml the titer of the virus 
ore be: 
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